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General
Introduction
Parts of this general introduction are published in Expert Opin Pharmacother.  
2006;7(13):1769-89 and Nat Clin Pract Rheumatol. 2007;3(12):681.
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Rheumatoid Arthritis
Rheumatoid arthritis (RA) is characterized by a symmetric chronic polyarthritis often 
leading to joint damage. The disease can occur at any age, but most frequently between 
40 – 60 years of age. RA affects 0.3 – 1% of the adult population, the disease occurs about 
three times as much in women as in men [1,2]. Although the clinical manifestations of RA 
are highly variable, symmetric arthritis affecting the metacarpophalangeal (MCP) joints 
and proximal interphalangeal (PIP) joints of both hands and the metatarsophalangeal 
joints of the feet (MTPJ) is the most characteristic early clinical feature. There is swelling 
with associated stiffness, warmth, tenderness, and pain with a characteristic morning 
accentuation of symptoms. 
Figure 1    Schematic representation of a normal joint and rheumatoid arthritis joint. In the healthy joint (a) the thin 
synovial membrane lines the non-weight-bearing aspects of the joint. In rheumatoid arthritis (b) the synovial 
membrane becomes hyperplastic and infiltrated by chronic inflammatory cells. Ultimately it develops into cartilage 
degradation and destruction of the adjacent bone. The latter is illustrated on the X-rays of the 2nd, 3rd and 4th MCP-
joints of a normal hand (c) and a hand of a patient with established RA (d).[7,8]
In addition to the joints, RA can also affect organs such as peri-articular tissue, skin, 
eyes, lungs and peri-articular tissues. The incidence of death from cardiovascular disease, 
infection and cancer is also significantly higher for individuals with RA than in the general 
population. [3,4,5] The effects of RA—joint damage, pain, fatigue and disability— finally 
also limit patients’ ability to participate in and perform their normal daily activities, 
including work, social and leisure activities [6]. 
Treatment outcomes 
The ultimate goals in managing RA are therefore reduction of pain and discomfort, 
prevention of loss of normal joint function and deformities, maintenance of normal 
physical, social and emotional function and capacity to work. [1,2,9] In RA there is a 
temporal sequence linking disease activity to destruction, with joint damage being a 
consequence of the active inflammatory process and disability being determined by both 
inflammation and damage. Early in the course of the disease, impairment of physical 
function is primarily related to disease activity, while later on, this association is partly 
superseded with damage [9]. This reveals that damage and irreversible disability are a 
consequence of time exposed to high disease activity. Therefore, reducing disease activity 
with early therapeutic intervention is the key to minimize joint damage and functional 
decline (figure 2) [2,9]. 
Figure 2    Effect of disease-modifying antirheumatic drug therapy. Disease-modifying antirheumatic drugs 
(DMARDs) will interfere with the disease process at any time point, and will lead to a deflection of the slope of 
progression from its natural course. The ideal situation would be to diagnose and treat rheumatoid arthritis early; at 
best, before damage has occurred.[10]
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 Process and Outcome measurement
Effects of treatment on disease activity can be measured either as relative improvement 
or in terms of the absolute value of disease activity that is reached. The most widely used 
response criteria are, in particular, the American College of Rheumatology (ACR) criteria 
and the Disease Activity Score (DAS). Although the ACR-criteria  have been widely used as 
outcomes for clinical trials in RA, it only provides relative measures of response and cannot 
be used to describe a patient’s disease activity at a specific point in time or to compare 
disease activity states between individual patients or cohorts of patients. 
The Disease Activity Score (DAS) is a compound index that provides an absolute value 
of disease activity. The DAS28 version of the DAS is calculated from 4 parameters: the 
number of swollen and tender joints from a total of 28 joints, the erythrocyte sedimentation 
rate and the visual analogue score for general health as estimated by the patient [11]. 
Using these data the DAS28 provides a number on a scale from approximately 0 to 9 
indicating the current activity of the patient. An absolute level of disease activity can be 
selected as a clinically meaningful goal for therapeutic intervention; with a value of ≤3.2 
defined as the threshold for a low disease activity state and <2.6 as the threshold for 
remission. [12]  Alternatively, the European League Against Rheumatism (EULAR) response 
criteria combine the DAS28 at the time of evaluation with the change in DAS28 between 
two time points, and enable the user to define improvement or response to treatment. [12] 
EULAR-responders are patients with a significant decrease in DAS28 score (>1.2) upon 
treatment and patients with a moderate change in DAS-28 score (≤1.2 and >0.6) and low/
moderate disease activity (≤5.1).
Apart from assessing the process of the disease (disease activity) it is also important to 
objectify the outcome of the disease (joint damage: the result of the disease process over 
time). This is usually done in clinical studies by assessing the presence and size of erosions 
and joint-space narrowing and assigning a numeral value to the observed articular 
destruction. These values allow longitudinal assessment of joint destruction for an 
individual patient and comparison of articular disease between groups. 
Currently, the most frequently used method to assess of joint-space narrowing and 
erosions is the modified Sharp score.[13,14]
Finally, physical functioning is one of the most important outcomes in RA given the 
impact of its impairment on the person, the family, and society. Various instruments have 
been developed to capture disability and its consequences on quality of life, and the most 
frequently used ones in RA are the health assessment questionnaire (HAQ) disability index 
and the short form-36 (SF-36), including its physical component subscale [15,16].
RA treatment
Treatment of patients with RA can be divided in non-pharmacological and pharma-
cological treatment:
 1 non-pharmacological treatment:
Management of RA begins with effective communication between physician and 
patient as it is important to educate the patient and the family about the nature and the 
expected course of the disease. Other nonpharmacological options include a wide range 
of modalities, such as exercise therapy, physical modalities, ortheses and self-management 
interventions. The evidence of effectiveness varies among the different non-
pharmacological modalities, with relatively strong support for exercise and self-
management interventions, and modest support for joint protection programs, specific 
orthoses and comprehensive care interventions. [17] 
 2 pharmacological treatment:
Traditionally, RA has been treated with non-steroidal anti-inflammatory drugs (NSAIDs) 
and disease modifying antirheumatic drugs (DMARDs, figure 3).  DMARDs (such as 
methotrexate (MTX), sulfasalazine, hydroxychloroquine, leflunomide, glucocorticoids and 
their combinations) can be highly beneficial for controlling inflammatory disease activity 
and reduction of joint destruction in RA [18-19]. DMARD therapy early in the course of RA 
slowed joint destruction more effectively than delayed use as irreversible joint damage is 
already appearing during the first months of RA.[9,18] Furthermore, early damage is a 
determinant for long-term functional consequences. To limit the development of joint 
damage as much as possible, early and adequately dosed treatment with DMARDs is 
therefore warranted in the early stage of RA. [1,2,9]
Due to it’s favorable efficacy/toxicity profile and low costs, MTX is currently the first 
choice for initial therapy. [18-20] If there is insufficient response and/or adverse effects 
due to MTX, another DMARD may be selected or added.
The discovery that the mainly macrophage-derived proinflammatory cytokine tumour 
necrosis factor alpha (TNFα) plays a important role in the RA process has led to the 
introduction of monoclonal antibodies and soluble receptors aimed at neutralizing the 
excess TNF: adalimumab and infliximab are monoclocal antibodies whereas etanercept is 
a soluble receptor binding TNFα. [1] A fourth anti-TNFα DMARD golimumab is currently 
under development and will be available soon. Besides TNF inhibitors, four other 
biotechnology derived therapies (“biologicals”) are currently available: the co-stimulation 
blocker abatacept, the B-cell depleting antibody rituximab, and the interleukine-1 and 
interleukine-6-antagonists anakinra and tocilizumab respectively. 
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Figure 3    Inter-relationship between disease activity, joint damage, and reversible or irreversible functional limi-
tation, and differences in effectiveness of various therapeutic principles. (Dotted arrows indicate inhibition) [21] 
Optimization of pharmacological treatment
Despite the availability of different treatment options and strategies for RA patients, 
the response to treatment with DMARDs is still suboptimal. For example, only 
approximately 40% of the patients show a good clinical response with MTX monotherapy 
and 30% discontinue treatment due to adverse effects. [19] Furthermore, although 40-
60% of the patients treated with anti-TNFα agents meet the American College of 
Rheumatology (ACR) 50% improvement criteria, these results also reveal that up to 60% of 
patients with RA do not reach the clinical relevant 50% improvement.[20] Strategies to 
optimize the pharmacological therapy of RA are therefore warranted; three potential 
strategies to improve the efficacy of pharmacological treatment in RA are possible and 
these are discussed below.
 1 Optimization pharmacological treatment: improving adherence
The full benefit of effective therapies can only be achieved if patients follow treatment 
regimens closely. Adherence, or the extent to which patients take medications as 
prescribed, is however low in chronic medical conditions: approximately 50% of all people 
with chronic medical conditions do not adhere to their prescribed medication regimens 
[22,23]. Reported levels of adherence in people with RA on DMARDs are slightly higher, 
varying from 58-82%. [24-27] Currently, most interventions to improve adherence to 
therapy have proven to be of limited effectiveness. [23]
Knowledge of factors associated with medication adherence in RA can help physicians 
to identify patients who would benefit from interventions to improve adherence. Few 
studies, however, have examined adherence to DMARDs in patients with RA. And although 
a wide range of variables have been identified as being linked to adherence to medication 
in general, none of these variables have however been consistently shown to be related to 
adherence across the different studies. [24] Thus, neither sociodemographic, nor 
biomedical, nor psychological variables seem powerful enough as a possible screening 
tool for non-adherent patients [24-30].
Adherence seems to be a complex phenomenon that cannot be explained to a 
sufficiently extent by a single factor or psychological variable. Therefore, several models 
have been developed in an attempt to understand nonadherence. The most widely used 
model, the Health Beliefs Model, hypothesizes that individuals will adhere with health 
regimens if they regard themselves as having or being susceptible to the condition in 
question, if the condition has serious current or future consequences, if the action would 
be beneficial, and if they feel that barriers to action are outweighed by the benefits. 
Patients consider whether their beliefs about the necessity of medication outweigh their 
concerns about potential adverse effects of taking them. [31] Thus, besides practical 
barriers like forgetfulness, clinicians should also be sensitive to personal beliefs that may 
impact medication adherence, and discuss the patient’s beliefs about necessity and 
concerns about medication.
 2 Optimization pharmacological treatment: disease activity guided treatment
A second step to increase the efficacy of DMARD treatment in addition to the 
improvement of adherence is the triad of close monitoring of disease activity, setting 
goals for low disease activity and adapting the treatment.[32-38] Several studies confirmed 
that disease activity guided treatment improves the effect of RA-therapy considerably 
compared with routine care [34-38]. However, a disadvantage of disease activity guided 
treatment is that it takes time to evaluate the effectiveness of treatment while titrating 
the dose (dose escalation/DMARD change in patients with moderate/high disease activity 
and dose decrease in patients with sustained low disease activity). This is associated with 
prolonged non-low disease activity, increase costs and the risk for adverse events as a 
consequence of the longer time period with higher disease activity while titrating the 
dose. 
 3 Optimization pharmacological treatment: therapeutic drug monitoring
Therapeutic drug monitoring of serum biological levels could be a third strategy to 
improve efficacy as these drugs have large inter- and intra-individual variability in 
pharmacokinetics and long elimination half-lives. Data derived from both rheumatology 
and gastro-enterology patients suggest that serum trough concentrations of (anti) 
infliximab, (anti)adalimumab and etanercept may be used to optimize dose regimens 
and prevent prolonged use of ineffective therapy. In general, at steady state, the maximum 
therapeutic effect appears to occur in patients with serum trough concentrations ranging 
between 1 to 10 mg/L independent of the compound. Additionally, it is confirmed in 
studies with infliximab that clinical response in RA decreases considerably with serum 
infliximab trough levels under 1 mg/L. [39-43] 
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2.2 The effectiveness of a structural adherence assessment provided to the rheumatologist
Clinicians tend to overestimate medication adherence and inadequately detect poor 
adherence. [29,48-50] As a consequence they may miss important opportunities to 
intervene. Therefore it is hypothesized, that making the physician aware of patient’s non-
adherence, will help to improve communication about the topic of non-adherence in 
patients at risk. Self-report measures, including interviews, questionnaires and diaries, 
are the most feasible instruments to identify non-adherent patients in routine care. 
Currently, there is only one validated rheumatology specific adherence questionnaire: the 
Compliance-Questionnaire-Rheumatology (CQR), [51,52]. This questionnaire is a useful 
instrument in clinical practice. Chapter 2.2 describes a within-subject controlled 
prospective cohort study describing the changes in adherence and beliefs of the patient 
as indicator of the effectiveness of a structural adherence assessment provided to the 
rheumatologist. 
Chapter 3
Therapy guiding by therapeutic drug monitoring of infliximab
Although several publications have suggested that assessment of (anti-) infliximab 
serum trough levels may be used to optimize infliximab treatment [40-43], certain 
important criteria must be met before a drug is considered a candidate for therapeutic 
drug monitoring. The most important criteria [53] are: 
An assay to measure drug concentrations is available;
There is a large interindividual variability in pharmacokinetic parameters;
A good relationship exists between plasma drug concentration and therapeutic or 
toxic effect;
The therapeutic effect can not be easily and completely assessed by the clinical 
observation;
There is a narrow range of concentrations that are (cost)effective and well tolerated.
3.1 Validation of an enzyme-linked immunabsorbent assay for the bioanalysis of infliximab 
in human serum.
With respect tot the first criterion: a validated accurate, precise and specific assay for 
the measurement of infliximab in serum is necessary to adequately detect and quantify 
infliximab concentrations in serum. Therefore, in chapter 3.1 a full validation of an 
infliximab-enzyme linked immunosorbent assay (ELISA) to determine the concentration 
of infliximab in serum samples from RA is described.
3.2 Downtitration of high dose infliximab in patients with rheumatoid 
Individual adjustment of infliximab treatment based on actual disease activity, instead 
of subjective clinical judgement, could prevent possible unwarranted dose escalation. In 
this chapter the percentage of RA patients treated with infliximab in which dose reduction 
could be reached without loss of clinical efficacy was assessed. Furthermore the feasibility 
of disease activity guided infliximab dose adjustments was also tested. Finally, it was 
studied whether the therapeutic effect could be readily and completely assessed by 
measuring the disease activity or that serum trough levels of infliximab could give 
The large inter- and intra-individual variability of pharmacokinetics of anti-TNF agents 
could be partially explained by the development of antibodies to the administered 
compound [43-47]. The incidence of development of anti-biological antibodies is reported 
to be higher in patients receiving infliximab (13 to 60%), a chimeric monoclonal antibody 
containing a murine variabIe region, compared with the incidences reported for the 
fusion protein etanercept (< 5% non-neutralizing anti-etanercept antibodies) or the fully 
human antiTNFα-antibody, adaIimumab (8-17 %). 
Knowledge of the (anti-) infliximab serum-concentrations could therefore provide 
auxiliary information for the decision whether continuation of treatment with infliximab, 
dose escalation or de-escalation is necessary.
Aim and outline of this thesis
Although the triad of close monitoring of disease activity, setting goals for low disease 
activity and adapting the treatment (dose) accordingly improves the efficacy of RA-
therapy considerably [34-38], both improving adherence and assessment of serum trough 
levels could possibly further improve treatment outcome by optimizing disease activity 
and consequently delay radiological progression. Therefore, this thesis aims to further 
increase knowledge of two strategies that could help to improve the efficacy of DMARD/
biological therapy in RA. First, improving adherence to traditional DMARDs could not only 
increase the effectiveness of a drug, but it could also indirectly dealy the necessity of 
applying (more expensive) biological therapy as traditional DMARDs are more efficacious 
due to better adherence. However when despite adequate non-biological DMARD therapy, 
biologicals are indicated, this thesis aims to determine the added value of therapeutic 
drug monitoring of (anti)infliximab serum trough levels in patients with RA.
Chapter 2
Adherence in RA
2.1 Adherence in RA: extent and risk factors
To be able to improve adherence, factors should be known that are associated with 
medication adherence in RA. This will help us to target non-adherent patients and design 
interventions to improve adherence. Although six studies have examined adherence to 
treatment with DMARDs, no variables were found to be consistently and strongly related 
to adherence [26-30]. Adherence seems to be influenced by more subtle patient 
characteristics. Examples of such adherence influencing variables are patients’ beliefs 
about medication, satisfaction with medication information and coping [31]. However, 
these patient characteristics have not been assessed in a study in relation to adherence 
with DMARDs in RA using a systematic selected sample of RA patients. 
In the second chapter, results are described of a descriptive study which assessed the 
extent of non-adherence in an unselected group of RA patients who use DMARDs. 
Furthermore, this study tries to identify risk factors for non-adherence in order to identify 
adherent and non-adherent patients and to assess potential intervention targets.
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additional information about the efficacy of infliximab. (criterion 4) 
3.3 The course of (anti)infliximab levels and disease activity between an infusion 
cycle of two infusions in patients with RA
It is relevant to get more insight in the interindividual variability in pharmaco-
kinetic parameters (criterion 2) and the relationship between plasma drug 
concentration and therapeutic or toxic effects (criterion 3). This variability could 
partially be explained by the formation of human antichimeric antibodies against 
infliximab (HACAs) which occurs in 8% to 43% of the RA patients. [43-45]. These 
HACAs almost irreversibly bind and neutralize infliximab. However, until now, it is 
unknown at what moment patients develop subtherapeutical infliximablevels 
and/or detectable anti-infliximablevels. Furthermore, it is unknown whether pre-
infusion (anti)infliximab serum levels are predictive for (anti)infliximab levels in 
the preceding infusioninterval. Therefore in chapter 3.3, the course of (anti)
infliximab levels and disease activity between an infusion cycle of two infusions in 
patients with RA is prospectively described. 
3.4 The added value of measuring (anti)infliximab serum trough levels 
Given the fact that large infliximab doses, and thus high concentrations, are 
associated with more side effects in which lymphomas appears to be the most 
noticeable [54] and large doses of the expensive anti-TNF agents could also lead to 
intolerable high costs, therapeutic drug monitoring of infliximab also seems to 
fulfil criterion 5 (a narrow range of concentrations that are (cost)effective and well 
tolerated). However, no prospective study so far has attempted to explore the test 
characteristics of infliximab and anti-infliximab serum trough levels in a cohort of 
patients being treated based on disease activity. Therefore, in this chapter a 
prospective cohort of RA-patients treated with infliximab is described. In this 
cohort the added value of measuring infliximab serum trough levels above disease 
activity guided treatment was studied in order to early predict (1) which patients 
could achieve low disease activity and (2) which patients receive sub-, supra- or 
non-therapeutical dosages.
3.5 The effect of rituximab on anti-infliximab antibodies
Rituximab, a chimeric monoclonal antibody that selectively depletes CD20-
positive B lymphocytes, could potentially inhibit the human antibody response 
against infliximab. Therefore, chapter 3.5 describes whether treatment with 
rituximab could be an effective intervention to diminish anti-infliximab antibody 
formation in patients with RA formerly treated with infliximab. 
Chapter 4
General discussion
Finally, in chapter 4 the results presented in this thesis are discussed into a 
broader perspective. Also clinical recommendations and directions for future 
research are provided.
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Abstract
Objectives 
Non-adherence in patients with rheumatoid arthritis (RA) using Disease Modifying 
Anti Rheumatic Drugs (DMARDs) may result in unnecessarily high levels of disease activity 
and function loss. The aim of this descriptive study is to assess adherence rates with self-
report measures in a large random population and tries to identify potential risk factors 
for non-adherence
Methods 
A randomly selected sample of 228 RA patients using DMARDs was invited for a 
standardised interview. For each medicine, the patients were asked about adherence, 
consumption and perceived (side-)effects. After the interview, the patients received self-
report questionnaires to assess adherence (Compliance Questionnaire Rheumatology 
(CQR) and the Medication Adherence Scale (MARS)), coping, beliefs about medicines, 
satisfaction about medicine information and physical functioning. Subsequently, 
associations between adherence and demographics, clinical characteristics and patient 
attitudes were examined.
Results 
Depending on the instrument used, 68% (CQR) and 60% (MARS) of the patients were 
adherent to DMARDs. Non-adherence was not associated with demographic and clinical 
characteristics, satisfaction about information, medication concerns and coping styles. 
The disease duration, the number of perceived side-effects and beliefs about the necessity 
of the medicine were weakly associated with adherence. 
Conclusion
In this large study with a random RA population, 32-40% of the patients did not adhere 
to their DMARDs prescription. As none of the possible risk factors were strongly related to 
adherence, no general risk factor seems to be powerful enough as a possible screening 
tool or target for adherence-improving interventions. This implicates that non-adherence 
barriers should be assessed on an individual basis. 
Introduction
Disease Modifying Anti Rheumatic Drugs (DMARDs) reduce disease activity and 
radiological progression and improve long term functional outcome in patients with 
rheumatoid arthritis (RA). [1]. However, patient adherence to DMARDs treatment is a 
prerequisite for these positive effects. Adherence, or the extent to which patients take 
medications as prescribed, is low in chronic medical conditions: approximately 20% to 
50% of patients do not take their medications as prescribed. [2, 3,4 ]
Adherence levels in RA patients on DMARDs have been studied in three relatively small 
studies (N= 26-49), with reported adherence levels ranging from 58 to 82%. [5,6,7] . Studies 
including both DMARD-users and NSAIDs users [8,9,10] reported similar adherence levels. 
However, the patient selection methods used in these previous studies do not exclude 
selection bias. For example, patients were invited by verbal or written invitation without 
random selection or systematic inclusion. Therefore, a larger study using non-biased 
patient inclusion is needed to obtain a reliable estimate of adherence levels in RA. 
In order to be able to improve adherence, non-adherent individuals have to be identified. 
[11]. The most feasible way to identify non-adherent in clinical practice is by using self-
report measures. Compared to other more intrusive measures, self-report measures are 
characterised by low costs, minimal participant burden, ease and administrative speed, 
flexibility in terms of mode of administration and timing of assessment. However, self-
report measures of adherence are not without drawbacks, including social desirable 
answers, and recall bias. Currently, there is only one validated rheumatology-specific 
adherence questionnaire: the Compliance-Questionnaire-Rheumatology (CQR). [12,13]. 
Adherence questionnaires can also be used to identify variables related to non 
adherence. However, although previous studies in rheumatoid arthritis identified a 
variety of sociodemographic, psychological (self-efficacy) and/or clinical variables related 
to adherence, none of these variables were consistently related in all studies. [5-10]. 
Therefore, it has been concluded that adherence seems to be influenced by less visible and 
more subtle patient characteristics. For example: patients’ attitudes towards or beliefs 
about taking medication, satisfaction with medication information and coping [14]. As 
yet, these patient characteristics have not been assessed in a study in relation to adherence 
with DMARDs in RA using a systematic selected sample of RA patients. 
The purpose of this descriptive study is therefore to assess the extent of non-adherence 
in an unbiased group of RA patients who use DMARDs. Furthermore, this study tries to 
identify demographic, clinical (drug use, side effects and physical functioning) and 
psychological (beliefs and cognitions) risk factors for non-adherence in order to identify 
adherent and non-adherent patients and to assess potential intervention targets. 
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 1 the Compliance Questionnaire on Rheumatology (CQR) 
which has been validated in patients with inflammatory rheumatic diseases against a 
Medication Event Monitoring System (MEMS-device). [13] The 19 item-CQR compares well 
with electronic monitoring over 6 months with a sensitivity of 98%, a specificity of 67% 
and an estimated kappa of 0.78 to detect non-adherence.[13] Responses to the CQR items 
multiplied by weighting scores were compared with the cut-off score for 80% adherence. 
The Cronbach’s alpha of the CQR in this study was 0.72. 
 2 the Medication Adherence Report Scale (MARS)
a questionnaire developed to measure adherence for a wide range of medication 
regimens. The scale consists of five non-adherence behaviours that are mainly intentional 
and are rated for frequency on a five-point scale.[16]. Among patients with asthma, 
diabetes and hypertension the MARS proved internal reliable with Cronbach’s alphas 
ranging from 0.67 to 0.90. [R Horne, Personal communication 2007]. The MARS measures 
adherence in a continuous scale, rather than as a dichotomous division between adherent/
non-adherent categories. However, in a study with renal transplant recipients a MARS-
score of 23 or less was regarded as non-adherent. [17]. In this study, adherence was also 
defined as a MARS total score > 23. The Cronbach’s alpha of the MARS in this study was 
0.78.
 3 a direct question during the patient interview: 
“Do you sometimes decide to skip a dose or do you sometimes forget a dose?” (1=never, 
2= once a month, 3= 3 times a month, 4=once a week, 5=several times a week and 6=I 
never take this medicine.) In this study, one missed dosage a week was defined as the cut-
off score for non-adherence.
Beliefs about medicines
Patient beliefs about medicines were assessed using the Beliefs about Medicines 
Questionnaire (BMQ), which has been validated for use in patients with somatic chronic 
illnesses [18]. The BMQ measures patient beliefs about the necessity of a prescribed 
medication to control their illness, and their concerns about the potential adverse 
consequences of taking the medication. Beliefs about necessity and concerns are both 
measured with 5 items rated on a five-point Likert scale. Hence, the total scores of the 
Necessity and Concerns Scales range from 5 to 25, with higher scores indicating stronger 
beliefs. Among general medical patients the subscales have reported Cronbach’s alphas of 
0.86 for the necessity scale to 0.51 for the Concerns scale. In this study we found a Cronbach’s 
alpha of 0.81 (necessity scale) and 0.66 (concern scale). 
Satisfaction about medicine information 
The Satisfaction about Medication Scales (SIMS) consist of 18 items which measure 
patient evaluation of information received about the different aspects of their medicines. 
For each item, participants can indicate whether the amount of information they have 
received is “too much”, “about right”, “too little”, “none received” or “none needed”. The 
SIMS items can be summarised under two topic headings or sub-scales: the action and use 
Patients and Methods
Participants
Patients using oral or subcutaneous DMARDs who fulfilled the American College of 
Rheumatology (ACR) criteria for RA visiting the outpatient clinic of the Sint Maartenskliniek 
between December 2004 and May 2005 were considered for inclusion in the study.[15] 
Patients were included in the study if their next regular check-up was scheduled either on 
a Thursday or Friday as on these days the specialised pharmacy assistant was available. 
Reasons for exclusion from the study were: illiteracy, life threatening disorders and severe 
mental disorders. All other patients, regardless of the disease duration, the seriousness of 
their condition, recent surgery or co-morbidity, were included.
Methods
Two weeks before the scheduled visit to the rheumatologist, patients received an 
invitation by mail for a medication interview with a specialised pharmacy assistant. This 
invitation was accompanied with three questionnaires: two questionnaires assessing 
adherence (CQR and MARS) and one questionnaire assessing beliefs about medication 
(BMQ). If two or more patients had an appointment with a rheumatologist at the same 
moment, the patients were selected in alphabetical order for an appointment with the 
specialised pharmacy assistant. The 15-20 minute interview, standardised in a written 
protocol, took place immediately after the patient’s visit to the rheumatologist. As part of 
the interview, the patients were informed about the nature of the study and informed 
consent was obtained. During the interview the patients received a set of standardised 
self-report questionnaires  (SIMS, HAQ, UCL). They were asked to complete the 
questionnaires at home and return them by mail. 
Assessed variables
Demographics and clinical characteristics 
Each interview started with an assessment of demographic variables: age, gender, 
marital status, education and smoking. During this interview, for each individual 
medicine, inquiries were made in a structured order to check how the medication was 
taken. Whether the patient attributed certain (side-)effects to a specific medicine was 
questioned with the question “Do you experience side effects? And if yes, than which?”. 
Self-reported adherence 
Adherence was assessed with three self-report measures: (1) Compliance Questionnaire 
on Rheumatology (CQR), (2) the Medication Adherence Report Scale (MARS) and during (3) 
an interview based self report. As the CQR does not directly measure adherence but 
partially relies on behavioural items, the use of the CQR could lead to a falsely increased 
correlation between specific cognitions and adherence measured. Therefore, the CQR was 
combined with the Medication Adherence Report Scale (MARS). 
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Results
Demographics and clinical characteristics 
Between December 2004 and May 2005 a total of 1419 patients with RA on DMARDs 
were scheduled to visit our outpatient rheumatology ward. The 692 patients visiting the 
clinic on a day scheduled for this study (Thursday or Friday) were considered for inclusion 
in the study. For each time slot, an average of three patients had an appointment with a 
rheumatologist. Within each time slot patients were selected using alphabetical order 
resulting in 235 patients who were invited to participate in this study, 228 of whom (96% 
of the invited patients) agreed to take part in the study and returned completed 
questionnaires. Reasons for not participating were unrelated to the content of this study. 
Demographic characteristics, medication use, and physical functioning of the study 
population are described in table 1. Most patients used methotrexate (56%), prednisolon 
(18%), hydroxychloroquine (10%), etanercept (8%), sulphasalazine (8%) or adalimumab 
5%) as Disease Modifying AntiRheumatic Drug.
In only 17% of the patients the  prescribed medication was restricted to DMARDs and 
analgesics. All other patients used additional medication. The most frequently used 
medicines were those that prevent or treat gastro-intestinal complaints (30% of the 
patients), osteoporosis (16% of the patients) and cardiovascular diseases (36%). Fifty-eight 
percent of the patients reported side-effects and the most frequently reported side-
effects were GI-complaints. The patients attributed these complaints to the following 
medicines (% of patients with side-effects): corticosteroids (52%), DMARDs (39%), 
biologicals (27%), bisphosphonates (20%), NSAIDs (16%) and cardiovascular medicines 
(11%).
Table 1    Demographic and clinical characteristics of included patients (n = 228).
Mean age (years) 56.2 (±12.2)
Female (%) 67.5
Married/living together (%) 84
Education level (%):
Primary (0-6 years education) 15
Secondary (7-12 years education) 67
Higher (> 12 years education) 18
Tobacco use (%): Non smoker 77
Number of medicines (median, percentile 25-75) 5 (3-7)
Disease duration (years) 4.6 (± 3.3)
HAQ (mean (SD)) 0.93 (± 0.63)
 
of medicines and the potential problems of medication. For the total satisfaction score, 
the percentage of patients satisfied with information is assessed by calculating the 
percentage of patients who rated scores of ‘about right’ or ‘none needed’ as satisfied. The 
complete SIMS showed a good internal reliability with a Cronbach’s alpha ranging from 
0.81 (assessed in a sample of insulin-treated diabetes patients) to 0.91 (cardiac 
rehabilitation. [16]. The Cronbach’s alpha of the SIMS in this study was 0.87. 
Coping 
The Utrecht Coping List (UCL) [19] was used to measure styles of coping with stress. The 
UCL consists of seven subscales, with 47 items, representing different general stress-
coping styles. The different styles are: active problem solving, palliative reaction, 
avoidance, seeking social support, passive reaction, expression of emotions and 
comforting cognitions. In several Dutch populations (elderly people, patients with chronic 
conditions and a sample of the Dutch population), the UCL has been found to have 
satisfactory psychometric properties [19], with Cronbach’s alphas ranging from 0.64 to 
0.82. The Cronbach’s alpha of the UCL in this study ranged from 0.61 (comforting cognitions) 
to 0.85 (active problem solving). 
Physical functioning 
Physical functioning was measured using the validated Dutch version of the Health 
Assessment Questionnaire (HAQ). [20]. This self-administered questionnaire consists of 8 
categories, each of which has at least 2 component questions.The average of these scores 
represents a physical functioning score. The HAQ has been found to have good criterion 
validity (correlations between questionnaire or interview scores and task performance 
0.71 - 0.95) as well as test–retest reliability (correlations 0.87–0.99)
Ethical approval
Ethical approval was obtained from the Ethics Committee Nijmegen-Arnhem. (METC).
Data analysis
Descriptive statistics were provided using mean (+/- SD) or median (p25-p75) values 
depending on the (non-) parametric distribution of measured variables. Potential 
demographic-related, disease-related and psychological variables were screened using 
univariate tests of the group difference (adherent versus non-adherent according to the 
dichotomized CQR) and the continuous CQR-scores, at a lenient level of significance 
without correction for multiple testing (α=0.05). This screening procedure was repeated 
with the MARS. We used Mantel-Haenszel Chi-square-tests to evaluate differences in 
proportions. Two-tailed student’s t-tests were used to evaluate differences in means. 
While univariate analysis yielded much useful information regarding the relationship 
between individual variables and adherence, it did not supply any insight into how a 
number of variables might jointly affect adherence behaviour. Therefore, a stepwise 
forward elimination multivariate analysis was performed to study possible confounders. 
All variables with a significant univariate association  were planned to enter in a forward 
stepwise logistic regression model with the continuous adherence measured by the CQR 
as the dependent variable. The data were analysed using SPSS (version 12.0). 
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about potential medication problems (a score of 6.1 on a 9-point scale). (t=7.2, p<0.01).
Coping scores were similar to mean scores reported in similar studies [10]. The UCL 
subscores were (mean ± SD): active coping, 17.4 ± 3.8; palliative reaction, 17.8 ± 3.1; 
avoidance, 16.1 ± 3.3; seeking social report, 12.2 ± 3.4; passive reaction pattern, 11.0 ± 3.2; 
expression of emotions, 5.6 ± 1.6; comforting cognitions, 12.7 ± 2.2. None of the coping 
scales were related to differences in adherence.  
Using stepwise forward elimination procedure, with a removal level set at p=0.05, 
logistic regression of non-interacting variables resulted in a three-variable risk model 
(R2=0.11) consisting of: number of adverse effects (p<0.01), disease duration (p<0.01), 
necessity of the medication (p= 0.04). 
Associations with the MARS questionnaire
Similar results were found when either the dichotomized CQR or the dichotomized 
MARS were used to distinguish patient characteristics between adherent and non-
adherent patients. 
Table 2    Comparison between demographic, clinical and psychological characteristics of adherent and non-
adherent patients.  Adherence, measured with the CQR, is expressed both as dichotomous (< 80% or ≥ adherence) 
and as continuous variable.
Adherence expressed as 
dichotomous variable
Adherence expressed 
as continuous variable
non-adherent 
(n= 73)
adherent 
(n= 148)
P-value r P-value
Mean age (years) 54.3 56.9 0.12 0.10 0.16
Female (%) 51 (70) 100 (68) 0.7 - 0.6
Married/living together (%) 57 (78) 127 (86) 0.15 - 0.07
Education level (%):
Primary 8 (11) 23 (16)
Secondary 51 (70) 100 (67)
Higher 14 (19) 25 (17) 0.6 -.007 0.3
Tobacco use: Non smoker 54 (74) 116 (78) 0.5 - 0.9
Number of medicines (median) 5.0 5.0 0.5 0.08 0.2
Number of side-effects 
(median)
1 1.0 0.02*) -0.16 0.02*)
Disease duration (median, 
years)
3.9 3.2 0.05 -0.21 0.004*)
HAQ (mean ) 0.9 0.9 0.7 0.04 0.58
BMQ necessity score (mean) 19.1 20.3 0.02*) 0.11 0.11
BMQ concerns score (median) 16.0 15.0 0.95 0.05 0.5
SIMS action score (median) 19.0 19.6 0.8 0.03 0.6
SIMS adverse effects score 
(median)
22.0 22.0 0.6 -0.01 0.9
*) p  <0.05
Self-reported adherence
In the structured interview with the specialised pharmacy assistant, irrespective of the 
type of medication,  81% of the patients declared never to miss a dose, and 16% declared to 
miss one dose a month, at the most. Allowing less than one missed dosage in a week, these 
face-to-face answers suggest that 98.5% of the patients were adherent. Based on the CQR, 
67% of the patients were adherent with prescribed medicines. Using the MARS, 60% of 
the patients were rated as adherent.
Relationship between demographics/clinical characteristics and 
adherence
A number of demographic, clinical and psychological variables were tested for possible 
associations with adherence (table 2). In short, age, gender, marital status, education level 
and smoking were not significantly associated with adherence. Disease duration, however 
was found to be associated with adherence expressed as a continuous variable rather 
than  as dichotomous variable. In an additional analyses, adherence in recently diagnosed 
patients (disease duration < 3 years ago; N = 78) was compared with adherence in patients 
with RA of a longer duration (N = 155). More patients with recent onset RA were adherent 
compared with patients with RA of longer duration (respectively 76% and 62%; Chi-square 
= 4.1, p =0.05). Adherent and non-adherent patients did not differ in terms of the number 
of prescribed medicines, NSAID-use or physical functioning (HAQ). Less adverse effects 
were reported In the CQR-defined adherent group compared with the non-adherent 
group.
Relations between patient characteristics and adherence
The average levels of necessity beliefs were high (mean score = 19.9, ± 3.6); most patients 
believed in the necessity of their medication to maintain their health. The mean necessity 
score for CQR-defined adherent patients was 20.3 (± 3.5) compared to a necessity score of 
19.1 (± 3.6) in the non-adherent group (t=-2.4, p=0.02) (table 3). This statistical association 
could not be confirmed with the continuous CQR.
More than 90% of the patients also has one or several concerns about potential adverse 
effects. Most of the patients expressed their concern about potential long-term adverse 
effects of their medications and medication dependency. There was no significant 
difference between the mean concern score for adherent patients compared with non-
adherent patients. 
Patient satisfaction with medication information (table 4) was highest on the items 
concerning information on how to obtain follow-up prescriptions, on how to use the 
medication, the medicine’s name and what it is supposed to do (> 90 % satisfied patients). 
Patients were least satisfied (< 70 % satisfied patients) with information on the risks of 
side-effects (including drowsiness and the impact on their sex life), information about 
what to do when side-effects are perceived, the impact of combining medication with 
alcohol use and therapy length. There was no difference in satisfaction with information 
about medication total or subscale score between adherent and non-adherent patients. 
Both adherent and non-adherent patients were more satisfied about the information 
they received about effects and usage (7.3 on a 9-point scale) compared to information 
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Discussion 
Using a self-reported questionnaire, approximately two thirds of the patients in this 
large random selected sample were adherent to DMARDs. These levels of self-reported 
adherence are much lower compared to the 98.5% of the patients declaring themselves to 
be adherent when asked face-to-face by a specialised pharmacy assistant. Non-adherence 
is hard to identify using general characteristics: only the beliefs about the necessity of the 
medication, the perceived side-effects and the disease duration were weakly associated 
with non-adherence. The proportion of non-adherent patients (60%-67%) is in line with 
previous studies indicating that 60-80% of patients with rheumatoid arthritis on DMARDs 
are adherent. [5,6,7]. 
As a consequence, a significant proportion of patients is not adherent to medication 
and, therefore, there is a need to develop effective interventions to  improve adherence in 
RA. Current interventions in patients with chronic conditions are not very effective [4,21]. 
It has been suggested that the efficacy of these interventions can be improved by tailoring 
them to the patients’ main reason for non-adherence, as there are no barriers for adherence 
that apply to all non-adherent patients. [18, 22, 24, 25]. This is confirmed in the present 
study, in which we found that non-adherence is unrelated to demographic and clinical 
characteristics, satisfaction about information, concerns about medication and coping 
styles. 
Only three variables were related to adherence in this descriptive study: disease 
duration, the number of attributed side-effects of the medication and beliefs about the 
necessity of the medicine. Although adherence seems to be higher shortly after a diagnosis, 
efforts to improve adherence should not exclude patients with short disease durations as 
adherence is also not optimal in recent RA. 
The number of perceived side-effects is the second variable related to adherence. In the 
non-adherent group the number of reported side-effects was almost double the number 
reported by adherent patients. Although tempting, it is too early to assume that medication 
side-effects cause lower adherence. An alternative explanation could be that a critical 
attitude towards medication causes lower adherence and raises the perception of side-
effects. In general, the level of reported side-effects was high in this sample. A majority of 
the patients (58%) reported one or more medication side-effects. This proportion is 
slightly lower compared to earlier studies observing that 60-84% of the patients with RA 
reported side-effects. [13, 26]. 
Finally, the role of beliefs underlines the complexity of adherence. Beliefs in the 
necessity of medication are high in this sample. Nevertheless, adherent patients had 
stronger beliefs about the necessity of their medication than non-adherent patients. The 
association of perceived need for medication and adherence is consistent with previous 
findings in studies in people with RA using the BMQ. [12,26]. Despite strong beliefs about 
the necessity of their medication, patients in this sample simultaneously reported strong 
concerns about potential adverse effects, particularly in the long term. However, specific 
Table 3    Beliefs about the necessity and concerns in adherent and non-adherent patients (n = 221)
Necessity scale
(% agreeing or strongly agreeing)
Concern scale 
(% agreeing or strongly agreeing)
Necessity 1)  Adherent 
patients
Non-
adherent 
patients
Concerns Adherent 
patients
Non-
adherent 
patients
At present, my health 
depends on 
medication
83 75 Having to take 
medicines worries 
me
59 51
My life would be 
impossible without 
medication
80 78 I sometimes worry 
about the long-term 
effects of my 
medicines
79 89
Without medication I 
become very ill
58 52 My medicines are a 
mystery to me 
21 19
My future health 
depends on 
medication
77 66 My medicines 
disrupt my life
15 11
Medication protects 
me
81 86 I sometimes worry 
about becoming too 
dependent on my 
medicines
46 41
1) Although the total score on the necessity beliefs differed significantly (p=0.02) between the adherent and 
non-adherent patient, none of the individual items differed significantly.
Table 4    Satisfaction about medicine information in both adherent and non-adherent patients(n = 228) 
Effects and usage % satisfied Potential problems % satisfied
Medicine name 93 Which side-effects 72
Indication 94 Side-effect risks 64
Effects 81 What to do when side-effects 
occur
67
Mechanism 72 Interactions 77
Duration effects 75 Alcohol use 64
Perceived effects 73 Drowsiness 67
Duration medicine use 59 Impact on sex life 46
Usage 94 Missed doses 77
Follow-up prescriptions 91 Effects on the unborn child 81
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interventions should also incorporate personal beliefs that may impact medication 
adherence and discuss patient concerns about medication and side-effects. Future 
research is necessary to determine the efficacy of interventions that are tailored to 
individual primary reason(s) for non-adherence. Only non-adherent patients should be 
included in this intervention. 
 
concerns about medications did not relate to adherence, which is in line with previous 
research. [12]. Patients seem to make a cost-benefit analysis to consider whether their 
beliefs about the necessity of medication outweigh their concerns about the potential 
adverse effects. [12, 26]. The moderate internal consistency of the concerns subscale, 
however, implies that future research is necessary to investigate the relationship between 
different medication concerns.
This study is based on data gathered in a large study sample of RA patients with 
DMARDs. The selection of patients ensured that the research sample is representative of 
the patient population at our clinic. However, the study has several limitations. These 
include the misclassification of adherence due to the absence of a gold standard for 
adherence, a possible overestimation of adherence and problems in causal inference due 
to a crossectional design. 
There is no gold standard for the assessment of adherence. As a result, the adherence 
estimates of different studies of the same patient and medication group vary significantly 
depending on the measurement instrument used. [27]. Adherence seems to be 
underestimated by the MEMS-device and overestimated by patient self-report and pill 
count. [28] In this study, the CQR was chosen because is the only validated adherence 
questionnaire in rheumatology. However, the CQR partially relies on behavioural items 
which could automatically lead to circularity between  specific cognitions and adherence 
measured with the CQR. Therefore, in addition to the CQR a non-behavioural questionnaire 
(MARS) was also used and the results of these questionnaires did not differ. However, 
there is no published MARS validation study as yet. As a consequence, previous studies 
did not consistently use the same cut-off points to dichotomise the MARS scale in adherent 
and non-adherence patients. [29, 30]. Further studies are therefore needed to find the 
best MARS cut-off point. Additional research is also warranted to differentiate adherence 
rates between different types of drugs, as both the MARS and the CQR are designed for 
general, and not drug specific, adherence.
Another limitation of this study is a possible overestimation of adherence due to the so 
called “Hawthorne-effect”. Given the nature of the study, patients are aware of the fact 
that they are under observation, which may affect their normal behaviour and lead to a 
more conscious medication use and, therefore, better adherence.
Finally, the crossectional design implicates that, although variables related to adherence 
could be identified, no causal relationships can be assumed. Another disadvantage of the 
cross sectional design is selection bias due to selective survival. For instance, if non-
adherent patients are more likely to stop DMARD therapy, then our cross sectional-study 
may have included less non-adherent patients and therefore underestimate non-
adherence. Further research is needed to determine whether altering risk factors have an 
effect on the adherence rate. Furthermore, the design does not measure changes over 
time. Adherence is a dynamic process, and patients’ behaviour can change over time. [11, 
14, 27]. Therefore, longitudinal adherence behaviour patterns should be studied. 
In conclusion, non-adherence is a major problem that affects approximately one third 
of RA-patients who use DMARDs. Hence, there is a need to develop effective interventions 
to improve adherence in this patient group. Besides practical barriers such as forgetfulness, 
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Abstract
Objectives
We developed an instrument which provides the physician structured information 
about medication use and patient’s (non-)adherence. This study aims to determine the 
effectiveness of this instrument on adherence and medication beliefs in outpatients with 
Rheumatoid Arthritis (RA).
Methods
In this within-subject controlled prospective cohort study, 50 outpatients were assessed 
during three consecutive visits to their rheumatologist. At these three points in time 
patient’s adherence, medication beliefs, satisfaction about information about medication, 
and physical functioning were measured using validated self-report questionnaires. An 
intervention was scheduled during the second visit. The intervention consisted of a report 
in writing informing the physician about medication use and adherence to medication 
for this particular patient. Effectiveness of the intervention was  evaluated by comparing 
outcome measures at the third visit to the same measures assessed prior to the 
intervention.
Results 
At baseline, 30% of the patients (n=50) were non-adherent. No significant changes in 
adherence were found between the first and second visit prior to the intervention. 
Adherence did not change after the intervention, compared to both of the adherence 
assessments prior to the intervention. Beliefs about medication, patient’s satisfaction 
about information on medication and physical functioning were also not significantly 
altered. 
Conclusion
Supplying the rheumatologist a report with information about medication use and 
adherence did not change adherence or patient’s beliefs about medication. Further 
research is necessary to ensure effective support for adherence for individual RA 
patients.
Introduction
Pharmacotherapy is the cornerstone of treatment for rheumatoid arthritis (RA); both 
to decrease complaints and to alter disease progression. Furthermore, it is estimated that 
74% of patients with RA use medication to reduce side effects. [1] Finally, 56-80% of the 
RA-patients has comorbidity, which is often treated with medication [2-4]. As a 
consequence, a number of drugs are prescribed to patients with RA. A recent study 
conducted by our research group showed that an average patient with RA uses 5.4 drugs/
day (range: 2-19 drugs/day). [1]
However, the effectiveness of pharmacological therapy may be limited by inadequate 
patient adherence to medication. Adherence may be defined as the extent to which a 
patient’s behaviour (in terms of taking medication, following a diet, modifying habits, or 
attending clinics) coincides with medical or health advice.[5] Adherence rates to prescribed 
medicine regimes in RA patients are low, varying from 30–80%. [6]  Failure to take 
medication has important consequences. It not only reduces efficacy of the treatment, 
but also wastes healthcare resources. Therefore, interventions to improve adherence to 
medication in RA can make a major contribution to effective pharmacotherapy. 
Successful interventions on medication adherence are characterized by frequent 
interactions with the patient with an increased attention to adherence. [7] Furthermore, 
the effectiveness of these adherence interventions will improve by selectively targeting 
these interventions to non-adherent patients. However, a consistent finding in the 
adherence literature is that physicians are unable to identify these non-adherent patients 
correctly. Clinicians tend to overestimate medication adherence and inadequately detect 
poor adherence. [8-11] As a consequence they may miss important opportunities to 
intervene. 
It is hypothesized, that making the physician aware of patient’s non-adherence, will 
help to improve communication about the topic of non-adherence in patients at risk. 
Therefore, we developed a pharmacotherapeutic consult to provide the rheumatologist 
structured information about drugs used, side effects, and non-adherence risk. Using 
standardized, validated questionnaires the risk for non-adherence was estimated. The 
outcome of this assessment was reported to the rheumatologist in writing.
The aim of this study was to describe changes in adherence and beliefs as indicator of 
the effectiveness of a structural adherence assessment provided to the rheumatologist. 
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Measures
Adherence
Adherence was measured by the Compliance Questionnaire on Rheumatology (CQR), a 
19-item questionnaire which has been validated against a Medication Event Monitoring 
System (MEMS-device). [13] The CQR compares well with electronic monitoring over 6 
months with a sensitivity of 98%, a specificity of 67%, and an estimated kappa of 0.78 to 
detect non-adherence (< 80% adherence). [13]
The CQR consists of 19 statements on a 4-point Likert scale. Six items are stated 
negatively and are therefore recoded  to yield a positive score. The continuous CQR score 
is subsequently calculated according to De Klerk et al. by multiplying patient’s responses 
by weight. To obtain dichotomous CQR-scores (< 80% adherence) the continuous adherence 
score is compared with the cut-off score for 80% adherence. [13]
Beliefs about medicines
Patients’ beliefs about their medicines were assessed using the Beliefs about Medicines 
Questionnaire (BMQ), which has been validated for use in patients with somatic chronic 
illness [14] The BMQ measures patients’ beliefs about the necessity of prescribed 
medication for controlling their illness, and their concerns about the potential adverse 
consequences of taking it. Beliefs about necessity and concerns are both measured with 5 
items. Respondents indicate their degree of agreement with each individual statement on 
a five-point Likert scale. Scores for individual items are summed. Higher scores indicate 
stronger beliefs. 
Satisfaction about information on medicines
The Satisfaction about medication scales (SIMS) comprises of 18 items measuring the 
patients evaluation of the information received. Patients are asked to rate different 
aspects about the received information about medication. For each item, participants can 
indicate whether the amount of information they have received is “too much”, “about 
right”, “too little”, “none received” or “none needed”. For the total satisfaction score, the 
percentage patients satisfied with information is assessed by calculating the percentage 
patients who rated scores of ‘about right’ or ‘none needed’ as satisfied. [15] 
Physical functioning 
Physical function was measured using the validated Dutch version of the Health 
Assessment Questionnaire disability index (HAQ-DI) [16]. This self-administered 
questionnaire is composed of 8 domains of physical functioning dressing and grooming, 
arising, eating, transportation, walking, hygiene, reach, grip, and daily activities. 
Averaging the highest score of each dimension (0 (no disability) to 3 (serious disability)) 
results in a physical function score. 
Patients and Methods
Design
In this within-subject prospective cohort study, medication use and adherence was 
assessed during three regular consecutive visits of patients with RA to the rheumatologic 
outpatient clinic of the Sint Maartenskliniek, Nijmegen, The Netherlands. The pre-
intervention period between the first and second visit was considered to be the baseline 
period. The intervention was subsequently scheduled during the second visit and 
consisted of a report in writing about patient’s drug use and adherence rate which was 
supplied to the rheumatologist before the patient visited the rheumatologist. The effect 
of the intervention was finally measured during the third visit. The primary endpoint was 
defined as the proportion of non-adherent patients (defined as < 80% adherence) 
measured with the Compliance Questionnaire on Rheumatology (CQR).
Patients
Between December 2004 and May 2005 all patients with a definitive diagnosis of RA 
according to the ACR criteria [12] visiting the rheumatologic outpatient clinic of the Sint 
Maartenskliniek were included in the study in the case they were using oral DMARDS. 
Before inclusion, the patients were informed about the nature of the study and informed 
consent was obtained. To be retained for the analysis, patients had to visit the Sint 
Maartenskliniek for at least three times.  Reasons for exclusion from the study were 
illiteracy, life threatening disorders and severe mental disorders. All other patients, 
regardless of duration of the disease, seriousness of the condition, recent surgery or co-
morbidity, were included. 
Procedure
Two weeks before each visit to the clinic patients received  two questionnaires: the 
Compliance Questionnaire on Rheumatology (CQR) and the Beliefs about Medicine 
Questionnaire (BMQ). During the patient visit to the hospital, a 15-20 minute standardized 
interview with the pharmacy consultant took place. The consultants were instructed not 
to discuss adherence to medication with the patient. Patient’s actual drug use and 
perceived side effects were collected. Furthermore, patient’s answers to the questionnaires 
were entered in a computer-based system in order to generate patient’s personal rate of 
adherence and beliefs about medication. The outcome of this assessment was only 
reported in writing to the rheumatologist during the second and third visit, as the period 
between the first and second visit was considered as baseline period. Finally, the patients 
received after every visit a set of standardized self-report questionnaires to assess 
satisfaction about medication information and physical functioning. Patients were asked 
to complete the questionnaire at home and to return them by mail.
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Results
Recruitment and baseline characteristics
69 Eligible patients were invited to participate. 13 (18.8%) Patients were excluded as 
they did not visit the outpatient clinic for at least 3 times. Two (2.9%) patients  were 
excluded because they send incomplete questionnaires (> 4 CQR items) and four (5.8%) 
patients declined to participate. Therefore, 50 patients were finally included for analysis 
(figure 1). The baseline descriptive statistics of these 50 patients are depicted in table 1. 
The baseline HAQ-score was comparable to those reported in other cohorts of patients 
with RA.[6] Comparing in- and excluded patients revealed no differences in baseline 
characteristics. The median time between the intervention-visit and the post-intervention 
visit (next scheduled regular visit ) was 102 days (p25-p75: 85-155).
Figure 1    Flow of participants through the trial. 
Table 1    Baseline Characteristics of patients completing both assessments at inclusion 
Patient characteristics (n =50)
Age, mean (SD), y 55.2 (12.4)
Sex, female no. (%) 35 (70)
Disease duration, mean (SD), y 4.6 (3.5)
Non adherent according CQR, No. (%) 15 (30%)
Necessity score, mean (SD) 20.1 (3.0)
Concerns score, mean (SD) 14.8 (3.2)
HAQ, mean (SD) 1.0 (0.72)
Ethical approval
Ethical approval was obtained from the Ethics Committee Nijmegen-Arnhem.
 
Data analysis
Descriptive statistics were provided using mean (+/- SD) or median (p25-p75) values 
depending on the (non-) parametric distribution of measured variables. We used Mantel-
Haenszel Chi-square-tests to evaluate differences in proportions, and two-tailed Student’s 
t-tests to evaluate differences in means. Analysis of variance (ANOVA) was used to find the 
differences in continuous CQR-scores and beliefs between baseline, pre- and post-
intervention assessments. 
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Discussion
This study demonstrates that informing the rheumatologist about patient’s non-
adherence does not seem to be effective to improve patient’s adherence, and patient 
beliefs about medication. Therefore, our hypothesis that raising the awareness of the 
rheumatologist about the individual patients level of adherence will increase level of 
adherence could not be confirmed. 
One explanation for this finding could be that adherence is seldom discussed between 
patient and physician, even in the case when the physician is made aware of the patient’s 
(non)adherence profile. Research on recorded interactions between patients with chronic 
diseases and their physicians during regular visits showed that even when the topic of 
adherence was raised, it was not always discussed.  Furthermore, doctors commonly 
responded to reports of non-adherence by changing the medication or providing 
education. [17]. Observations show also that doctors rarely explore patients’ ideas, 
concerns and expectations or their understanding and intentions about therapy [18-20]. 
Doctors think they discuss management issues more often than is actually the case and 
interestingly, patients also tended to overestimate how much they were told and involved 
in the consultation [17]. However, physicians also express uncertainty about how to discuss 
non-adherence, felt that they lacked adequate training and/or counselling skills, find it 
hard to maintain an open and non-judgemental dialogue and indicate that they have 
limited time they can devote to discuss adherence related topics. [21-23]
This study is not without limitations. First of all, like all medication adherence studies, 
outcome data in this study is limited by potentially misclassification of adherence. 
Assessment of adherence is a difficult and complex undertaking. with no ‘‘gold standard’’ 
method [24-26]. For the present study, we choose the CQR as primary outcome measure. 
Although the CQR is validated against the electronic pill-caps, the applicability of the CQR 
in longitudinal studies is insufficiently established yet. Further studies to validate the CQR 
as a longitudinal instrument to measure different adherence rates in time is therefore 
warranted. Despite this difficulty in assessment, a large impact of the written reports to 
the rheumatologist does not seem to be very likely,  as none of the other variables in the 
study were affected by the intervention too.  However, we did not observe or record the 
consults of the rheumatologist and we therefore do not know what is really discussed 
with the patients. 
In this study, we used a within subjects design. A fundamental disadvantage of the 
within subjects design can be referred to as “carryover effects”. Participation in the pre-
intervention condition could theoretically effect the post-intervention phase. However, 
when a carry over effect should have occurred, it seems to be more reasonable that this 
would only increase adherence in the intervention condition as it is more likely that 
increased attention to medication use during the control condition, enforces adherence. 
Finally, the number of patients in the present study is relatively limited, which could result 
in a decreased power to detect differences. 
Influence of intervention on adherence and clinical outcome
Before the intervention, during the baseline period, non-adherence decreased from 30 
to 22%. The intervention, however, did not result in a further decrease of non-adherence, 
but resulted in a  slight increase (28% non-adherence).  None of the differences between 
adherence rates at baseline, before the intervention, and after the intervention are 
statistically significant (table 2). 
Patients beliefs about the necessity of their medication (expressed as the necessity 
score) declined non-significantly from 20.1 (± 3.0) at baseline to 19.3 (± 3.3) before the 
intervention and finally to 19.0 (± 3.1) after the intervention (p=0.6; before and after the 
intervention). Patients concerns about medication did not change significantly after the 
intervention. Finally, the satisfaction about information about medication was also not 
affected: from (13.7 (± 4.5) at baseline to 15.2 (± 3.6) and 14.6 (± 3.7) pre and post-
intervention. 
As expected, the intervention did not affect physical functioning (HAQ), the health 
assessment score in the intervention and in the control group remained almost stable 
compared to baseline, with a baseline HAQ of 1.0 (± 0.72) compared 1.0 (± 0.72) and 1.1 
(± 0.76)) before and after the intervention respectively. 
Table 2    Influence of the intervention on adherence and clinical outcome
Intervention (n=50)
Baseline (visit 1) Pré-intervention 
assessment 
(visit 2)
Post-
intervention 
Assessment 
(visit 3)
P-value
Non-adherent 
patients 
according to 
CQR, No. (%)
15 (30) 11 (22) 14 (28) p=0.68
CQR-score, 
mean (SD) 
(range)
-0.31
(± 1.24)
(-4.0 to 1.4)
-0.023
(± 1.09)
(-2.5 to 2.8)
0.008 
(± 1.16)
(-2.8 to2.5)
p=0.34
Beliefs: 
Necessity, 
mean (SD)
20.1(± 3.0) 19.3(± 3.3) 19.0 (± 3.1) p=0.19
Beliefs: 
Concerns, 
mean (SD)
14.8(± 3.2) 16.3(± 3.4) 15.2 (± 3.7) p=0.13
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Abstract
Infliximab is an effective treatment for several inflammatory disease states, including 
rheumatoid arthritis and inflammatory bowel disease. Although most patients achieve at 
least partial clinical response to infliximab, 30–40% of the RA patients on infliximab are 
non-responders. Data derived from both rheumatology and gastro-enterology suggest 
that pharmacokinetic data of infliximab potentially could help to predict treatment 
outcome and consequently optimize treatment. A prerequisite for applying therapeutic 
drug monitoring is however availability of a validated accurate and precise analytical 
method for the quantitative evaluation of infliximab. 
For this purpose, a quantitative enzyme linked immunosorbent assay (ELISA) for the 
quantification of infliximab in human serum was developed and validated. The calibration 
curves of the assay, ranging from 0.020- 12.5 ng/mL, had good quality over the concentration 
ranges tested. The within-day and between-day precisions (CV) ranged from 6.9 % to 
13.8% and from 5.7 % to 14.3 %, respectively. Both precisions and the results for accuracy 
fell within the ranges specified (average accuracy (RE) –8.3 to 4.0%). Lower and higher 
limit of quantification were 0.5 mg/L and 50 mg/L infliximab in undiluted serum 
respectively. No relevant interference between co-administered drugs and the accuracy 
and precision of this assay was detected.
The analytical performance of this infliximab ELISA indicates that this assay can be 
used for monitoring concentration levels of infliximab in human serum in order to help to 
optimize the dosing and scheduling of infliximab therapy. 
 
Introduction
Infliximab is a chimeric monoclonal antibody against TNFalpha, which has been proven 
effective and well tolerated in patients with Crohn’s disease (CD), rheumatoid arthritis 
(RA), psoriasis and ankylosing spondylitis. Although the majority of patients achieve at 
least partial clinical response to infliximab, 30–40% of the patients on infliximab is non-
responder [1,2]. Some patients will show no initial response, while others lose response 
over time or experience intolerable adverse effects. In order to maximize treatment 
outcome and to minimize the risk of adverse effects and unnecessary treatment costs, 
identification of predictors of (non)response is very important.
Large inter-individual pharmacokinetic profiles, observed in RA and CD patients, may 
partially account for variations in the efficacy of infliximab, and could therefore be a 
potential candidate to help to predict treatment outcome [3, 4]. Infliximab serum trough 
concentrations both in RA and in CD positively correlated with response [3,5,6]. This is 
illustrated by the fact that only half of the RA-patients with serum concentrations <0.1 µg/
mL achieved an American College of Rheumatology (ACR) 20 response, whereas half of 
those with serum concentrations >1 µg/mL had at least an ACR 50 response [6]. ACR20 and 
ACR 50 responses are defined as at least 20% respectively 50% improvement in both the 
tender joint count and the swollen joint count and at least 20%/50% improvement in 3 of 
5 other core set measures. A review of the available literature for all the anti-TNF biologics 
reflects that, at steady state, the highest proportion of the observed response appears to 
occur in patients with steady-state serum concentrations ranging between 1 to 10 μg/mL, 
independent of the chosen anti-TNF compound [7].
Because of the inter-individual variability in infliximab pharmacokinetics and the 
reported concentration-therapeutic efficacy relationships, infliximab treatment may be 
optimized by therapeutic drug monitoring based on measurements of its serum 
concentrations. A prerequisite for applying therapeutic drug monitoring is the availability 
of a validated precise and accurate analytical method for the quantitative evaluation of 
infliximab. This bioanalytical method validation should include all of the procedures that 
demonstrate that the quantification of infliximab in serum is reliable and reproducible 
for therapeutic drug monitoring. Therefore, this article describes the validation of an 
ELISA to determine the concentration of infliximab in serum samples from RA patients 
that received infliximab.
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Calibrators and validation samples
Calibration curves were prepared at infliximab concentration levels of 0.020-12.5 ng/
mL by spiking an appropriate amount of the standard solution in blank plasma. The 
calibration curve was prepared and assayed along with quality control (QC) samples. 
Validation samples were prepared in blank plasma at 0.2, 1.0, 5.0, 10.0, 50.0 and 200 mg/L 
infliximab. 
Assay validation requirements 
The quantitative determination of infliximab was validated by a set of parameters 
which are in compliance with the requirements as defined in the “Guidance for Industry 
for Bioanalytical Method Validation” [8] and the “Recommendations for the Bioanalytical 
Method Validation of Ligand-binding Assays to Support Pharmacokinetic Assessments of 
Macromolecules” [9]. 
Linearity and calibration standard
The linearity of the assay was evaluated by analysing seven standard curves consisting 
of six calibration standards using a four-parameter logistic regression algorithm to fit the 
response [optical density (OD)] versus concentration of infliximab. Goodness of fit was 
indicated by an average correlation coefficient of r ≥ 0.99. For the curve within a run to be 
acceptable, 15 %CV of the back-calculated value should be within 15% of the nominal 
concentration, except at the LLOQ where the value should be within 20% [9].
Accuracy, precision
Accuracy is the closeness of agreement between the measured value and the accepted, 
“true,” or reference value, whereas the precision of an analytical procedure expresses the 
closeness of agreement (degree of scatter) between a series of measurements obtained 
from multiple sampling of the same homogeneous sample under the prescribed conditions. 
Both inter-assay and intra-assay accuracy and precision were determined by analysing five 
replicates of five different concentrations of QC samples on three different days. One-way 
analysis of variance (ANOVA) was used to calculate the intra-and inter-day variation in these 
parameters. Accuracy is defined as the magnitude of systematic error, expressed as percent 
relative error (RE). Precision is defined as the magnitude of random error, expressed as 
percent coefficient of variation (CV). The interbatch precision (%CV) and the absolute mean 
bias (accuracy, %RE) should both be ≤15%. In addition, it is recommended that the method 
total error (sum of the %CV and absolute %RE) be ≤ 30 to be consistent with the in-study 
validation acceptance criteria. For the lower limit of quantification the percent deviation 
from the nominal concentration and the relative standard deviation had to be less than 20% 
[9].
Limit of detection (LOD) and Limit of quantification (LOQ))
The LOD is the smallest quantity of analyte that is detected and measured at a level 
that is significantly greater than the measurement (random) error of the blank at a 
prescribed level of confidence. The LOD was determined by analyzing 6 sets of samples 
without analyte (two rheumatoid factor negative and four positive samples). The LOD is 
Materials and Methods
Assay
Infliximab levels were determined by ELISA. A schematic representation of the assay is 
shown in figure 1. Mouse monoclonal antibody directed against TNFα (CLB TNF/7) was 
coated overnight at room temperature (2 µg/mL, 100 µL/well) on flat-bottom microtitre 
plates. Recombinant TNF (0.01µg/mL, 100 µL/well; Stratmann, Hannover, Germany) in 
high-performance ELISA (HPE buffer; 1:5 dilution in aqua dest.; Sanquin, Amsterdam, the 
Netherlands) was added for 1 hour. After washing with phosphate buffered saline/0.02% 
Tween (PBS-T), patients’ serum samples (100 µL/well) were added in different dilutions in 
high performance ELISA (HPE) buffer and incubated for 1 hour at 37°C. After washing with 
PBS-T (phosphate buffered saline/0.04% Tween), biotinylated rabbit antibodies directed 
against infliximab F(ab)2 were added into the wells (0.25 µg/mL, 100 µL/well; Sanquin, 
Amsterdam, the Netherlands). After incubation for 1 h at 37°C, the plates were washed 
with PBS-T. Streptavidine poly-HRP (1 mg/mL; 1:25.000 dilution in HPE buffer; Sanquin 
Reagents Unit, Amsterdam, the Netherlands) was added (100 µL/well) and incubated for 
30 minutes at 30°C. The ELISA plate was again washed with PBS-T and 100 µl of 3,3’,5,5’ 
tetramethylbenzidine solution (1:1 dilution in aquedest.; Uptima-Interchim, Montluçon 
Cedex, France) was added to each well and incubated for 15 minutes at 30°C. After stopping 
the reaction with 2M H2SO4 (100 µL/well), the optical density (OD) at 450 nm was 
measured with an ELISA reader (Bio-Tek ELx-808; Bio-Tek Instruments, Winooski, VE, USA). 
Results were related to a titration curve of infliximab in each plate. The ELISA thus captures 
infliximab through its ability to bind to TNFα. It does not bind immune complexes 
consisting of infliximab and TNF or infliximab bound by neutralising antngibodies. 
Figure 1    Schematic representation of the infliximab ELISA. The assay was conducted as described in the material 
and methods, section assay. 
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way of sample treatment. The accuracy of the quantification of these samples should be 
less than < 15%.
Refrigerator (4°C), freezer (-20°C) and room temperature stability during 2 months 
were demonstrated at low, medium and high infliximab concentrations (0.5, 5.0 and 200 
mg/L in human serum). Validation samples at each concentration level were allowed to 
remain at the refrigerator or at room temperature for 4 h prior to analysis. The accuracy 
of the quantification of these samples should be less than < 15% [9].
Stability of the assay plates, reagents and benchtop stability. 
Assay plates and buffer solution are freshly prepared before each quantification; 
further stability analysis seems therefore not necessary.
Validation results
Linearity and calibration standard
“Goodness of fit” was indicated by an average correlation coefficient of 0.9995 from 7 
standard curves. Obtained standard curves are depicted in figure 2. All back-fitted results 
for the standards were within 15% of their nominal concentrations. The mean % difference 
from theoretical for these back-fitted standards ranged from 0.2 to13.7 with %CV values 
from 0.1% to 4.2%, indicating the appropriate quality of the calibration curves. 
Figure 2    Obtained standard curves for the infliximab Elisa. Absorbance is plotted against serum concentration in 
mg/L
defined as the mean result of the optical density plus 3 times the standard deviation of 
these blank samples [10].
The lower limit of quantification (LOQ) is the smallest amount of analyte in a test 
sample that can be quantitatively determined with suitable precision and accuracy. The 
lowest standard on the calibration curve will be accepted as the limit of quantification if 
the analyte response at the LLOQ is at least 5 times the response compared to blank 
response. Analyte peak (response) should be identifiable, discrete, and reproducible with 
a precision of 20% and accuracy of 80-120% [8].
Specificity
Specificity is the property of an analytical method to unequivocally detect the target 
analyte, with minimal or no cross-reactivity to unrelated analyst. The interference of 
endogenous compounds was therefore investigated by analyzing blank plasma samples 
of 6 different patients with RA (Four rheumatoid factor (RF)-positive and two RF-negative 
patients). The responses of the 6 blank plasma samples should be less than 20% of the 
response of the LLOQ.  
Selectivity
Selectivity, a concept related to specificity, is the ability of an assay to measure the analyte 
of interest in the presence of other constituents in the sample. Selectivity was assessed by 
analyzing 6 plasma samples of 6 different patients with RA enriched with the LLOQ 
concentration. Possible interference with other anti-TNF agents (adalimumab and 
etanercept) and other frequently co-administered drugs in rheumatology (methotrexate, 
diclofenac and prednisolone) was tested by analyzing samples that contained peak values 
observed (in rheumatoid) arthritis patients: etanercept (2.6 mg/L), adalimumab (9.0 mg/L), 
methotrexate (1.1 µM/L after 15 mg sc), paracetamol (20 µg/mL after 20 mg/kg po), diclofenac 
(2.0 µg/mL after 50 mg po) and prednisolone (458 ng/mL after 2 dd 30 mg sc). 
Dilution linearity
Dilution linearity shows that the analyte of interest, when present in concentrations 
above the range of quantification (above ULOQ), can be diluted into the validated range. 
The effect of dilution on the measured concentration of infliximab was tested by preparing 
a spiked validation sample in human serum at a concentration of 60 mg/L (above 
calibration range). Three serial dilutions of the validation sample (1:40000, 1:160000, 
1:640000) were subsequently analysed. 
Sample stability 
Freeze/thaw stability in human serum was demonstrated at low, medium and high 
infliximab concentrations (0.5, 5.0 and 200 mg/L in human serum). Validation samples at 
each concentration level were subjected to three freeze/thaw cycles. A freeze/thaw cycle 
consists of keeping the validation samples frozen (-20°C) for at least 20 h and thawing at 
room temperature for at least 1 h. Each validation sample was then analyzed (n=6). The 
calibration solution was also subjected to three freeze/ thaw cycles to check for possible 
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Table 2    Precision and accuracy of the infliximab ELISA after co-administration of potentially co-administered 
drugs
Etanercept Adalimumab Methotrexate Prednisolone Diclofenac
Infliximab 
concentration 
(mg/L)
0.5 5 200 0.5 5 200 0.5 5 200 0.5 5 200 0.5 5 200
Accuracy (RE%) 19,5 17,2 1,6 18,8 7,7 1 4,9 12,3 2,8 5,4 18,8 5 1,8 12,5 0,1
Precision (CV%) 5.6 14.9 10.9 5.6 11.1 2.1 2.9 10.0 10.0 4.8 10.6 5.9 3.6 8.3 7.1
Dilution linearity: Three serial dilutions of the validation sample were tested with the 
resulting concentration covering the calibration range. The precision (% difference from 
exact value) for each diluted sample ranged from 1.0-11.9% with CV% values from 8.7-
11.5%.
Stability
The results of the stability tests under various conditions are listed in table 3. Under all 
conditions infliximab proved to be stable with recoveries ranging from 93.1 to 113.2% of the 
initial concentration.
Table 3    Stability of infliximab serum samples under various conditions
Statistics Concentration mg/l
Infliximab concentration mg/L 0.5 5.0 200
Freeze/thaw Precision (CV%) 5.0 7.2 8.6
Accuracy (RE%) -3.6 5.8 9.2
Room temperature Precision (CV%) 2.2 15.2 6.7
Accuracy (RE%) -0.7 -1.8 -0.7
4°C Precision (CV%) 3.8 2.4 3.4
Accuracy (RE%) -6.9 3.9 1.5
-20°C Precision (CV%) 2.3 13.2 8.1
Accuracy (RE%) 0.0 4.4 9.2
Accuracy and precision
The intra- and inter-assay performance data are presented in table 1. These results 
show that these method is accurate (average accuracy from –8.3 to 4.0 %) and precise 
(between day coefficient of variation (CV) : 5.7-14.3%, within-day CV: 6.9-15.3%). The 
accuracy and precision fell within the specified ranges. The lower limit of quantification 
was found to be 0.5 mg/L, whereas the higher limit of quantification was 50 mg/l. However, 
as we designed this assay for assessing infliximab concentration in therapeutic ranges, 
lower an/or higher infliximab concentrations were not aimed at and subsequently not 
measured in this validation experiment. 
Table 1    Intra-assay and inter-assay precision (coefficient of variation (CV) and accuracy (the percentage of the 
mean relative error (RE)) of the assay at various infliximab concentrations
Concentration mg/L
 0.5 1 5 10 50
Accuracy (RE%) - 8.3 -3.4 -11.6 4.0 -7.0
Precision (CV%) Intra-assay 13.8 15.3 6.9 9.9 9.5
Inter-assay 6.9 10.9 12.4 14.3 5.7
Total 15.4 18.8 14.2 17.5 11.1
Limit of detection (LOD), specificity and selectivity
The interference of endogenous compounds was investigated by analyzing 6 blank 
plasma samples of 6 different patients with RA. The average extinction was : 0.035 +/- 
0.00075, indicating that the lowest measured content from which it is possible to deduce 
the presence of infliximab with reasonable statistical certainty is 0.035 + (3 x 0.00075 )= 
0.037 as lower limit of detection. The average extinction of the lower limit of quantification 
is five times higher compared to the lower limit of detection, which complies with the 
recommendation that the response of the lower limit of detection should be less than 20% 
of the response of the LLOQ.  
Potentially co-administered drugs were tested (table 2), however there was no relevant 
interference between any co-administered drug and the accuracy and precision of this 
assay. 
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Conclusion
A precise, accurate and robust assay for infliximab is crucial for a better understanding 
of its biological effects and perhaps tailoring the therapy for individual patients. The 
infliximab assay described in this paper is rapid, accurate and precise with a quantisation 
range from 0.5-50 mg/L in human serum. This range covers clinical relevant infliximab 
concentrations, as maximum therapeutic effect appears to occur in patients with steady-
state serum concentrations ranging between 1 to 10 mg/L, and clinical response in RA 
decreases rapidly with serum infliximab trough levels under 1 mg/L [7, 11].
This robust assay opens therefore the way to determine the optimal level of infliximab 
that must be reached to achieve optimal clinical response, with limited side effects and 
costs. However, despite several publications suggesting that the assessment of (anti-) 
infliximab serum trough levels may be used to optimize infliximab treatment [1, 5,11, 15], it 
is still unclear when and how the quantification of infliximab can be used in clinical 
practice. Therefore, a prospective study is warranted to assess the added value of 
measuring infliximab serum trough levels to complement disease activity guided 
treatment. This would enable discrimination between patients with low disease activity 
and patients who are overtreated. 
Despite the increasing number of biological agents, an official specific guidance for 
bioanalytical methods validation for assays of macromolecules is currently lacking 
although streamlining of the method validation process is warranted. Currently only an 
industry consensus is available. This document makes specific recommendations for 
validation ELISAs to support pharmacokinetic assessments of macromolecules. [9, 12,13 
14]. Currently, the U.S. Food and Drug Administration (FDA) only describes the bioanalytical 
method validation of small-molecule drugs [8]. However, this guidance cannot be directly 
applied to macromolecules, due to the heterogeneous nature of macromolecules and the 
inherent variability of immunoassays. Thus, given the complexity and heterogeneity of 
these macromolecular therapeutics, as well as the methods routinely used to quantify 
these molecules, proper specific recommendations for validation of macromolecules is 
warranted for industrial, governmental and scientific purposes. 
Acknowledgements We thank Rob Aarnoutse, PharmD, PhD, pharmacist at the 
department of Clinical Pharmacy, Radboud University Nijmegen Medical Center 
(Nijmegen, The Netherlands) for his methodological support during the design of the 
validationprocedure. Futhermore, we like to thank Kim van Houten (technician) and 
Tom Lourens (quality manager) both at the Department of immunopathology of 
Sanquin Research (Amsterdam, The Netherlands) for analyzing the validation 
samples.
Sustained effect after 
lowering high dose 
infliximab in patients  
with rheumatoid arthritis: 
a prospective dose 
titration study.
Bart JF van den Bemt
Alfons A den Broeder
Gijs F Snijders
Yechiel A Hekster
Piet CLM van Riel
Bart Benraad
GJ Wolbink
Frank HJ van den Hoogen
Published in Ann Rheum Dis. 2008;67(12):1697-701
3.2
4 3.5 3.4 3.3 3.2 3.1 3 2.2 2 1
74
43.53.43.33.23.132.221
75
3.23.2Sustained effect after lowering high dose infliximab in patients
with rheumatoid arthritis: a prospective dose titration study.
Sustained effect after lowering high dose infliximab in patients
with rheumatoid arthritis: a prospective dose titration study.
Abstract
Objectives
In clinical trials only a small subset of patients with Rheumatoid Arthritis (RA) benefits 
from higher than standard dose of infliximab (> 3 mg/kg/8 wks). However, dose escalation 
of infliximab is frequently applied in clinical practice. Individual adjustment of infliximab 
treatment based on actual disease activity, instead of subjective clinical judgement, could 
prevent possible unwarranted dose escalation.
Methods
The infliximab dose of all RA patients treated at our centre was decreased from 5 mg/
kg to 3 mg/kg, leaving dosing intervals unaltered. Subsequently patients were followed 
for at least 3 infusions. At every visit DAS28, infliximab serum trough levels and anti-
infliximab-antibody levels were assessed. Inversed EULAR criteria (flare criteria) were 
used as endpoint.
Results
18 patients were included. Mean (± SD) DAS28-scores before dose reduction and after 
first and second low dose was 3.2 (± 1.2), 3.2 (± 1.8) and 3.3 (± 1.2) respectively (NS). One 
patient (6%, CI 0-17%) developed a persistent flare that subsided after increasing infliximab 
doses and one patient stopped infliximab because of a lupus like reaction. In all other 
patients (n=16) lowering infliximab resulted in unaltered disease activity. Infliximab 
levels showed that most patients had either low- (< 1 mg/l) or high (> 5 mg/l) serum trough 
levels. Anti-infliximab antibodies were detected in 4 patients.
Conclusion
Infliximab dosages of 5 mg/kg can be lowered in the majority of RA patients using 
DAS28 guided dose titration without increase of disease activity. Lowering the dose of 
infliximab should be considered in every patient receiving higher doses infliximab.
Introduction
Infliximab is a chimeric monoclonal antibody that binds with high affinity and 
specificity to TNF-alpha and neutralizes its biological activity. Several studies in both early 
as refractory rheumatoid arthritis demonstrate that infliximab gives rapid and sustained 
clinical response, delays radiographic progression, and improves functional status and 
health-related QOL.[1,2,3] The adverse effects reported in clinical trials were generally 
mild in severity. 
However, interpretation of the optimal individual dose of infliximab is not completely 
straightforward. Although in the two pivotal RCTs (ASPIRE [1] and ATTRACT [2,3]) low doses 
tended to be less effective then higher doses, this difference was only significant in the 
ATTRACT study with respect to the ACR50 (American College of Rheumatology) responders 
and not for the primary endpoint (ACR20). Based on these studies, at most 17% of the 
patients seems to benefit from doses >  3 mg/kg. In a recent dose escalation study 22% of 
the 360 patients seem to benefit from a dose > 3 mg/kg. [4] However, no control group 
without dose escalation was present in this study. Therefore, it can not be ruled that 
clinical improvement was also due to the natural course of the disease instead of the dose-
escalation. In conclusion, summarizing available studies, it seems that doses of > 3 mg/kg 
infliximab  are only necessary in a small subset of patients.
In clinical practice, however, higher doses (based on the subjective clinical judgment of 
the treating physician) are much more frequently used. Large clinical practice based 
observational cohort studies show that within 1 year in 22-51% of all patients the infliximab 
dose was escalated.[4,5,6,7] It could be postulated that a proportion of patients treated 
with higher doses of infliximab receive supratherapeutical doses. 
A possible solution for avoiding individual overdosing of antiTNF-alpha could be 
titration of the infliximab dose based on actual disease activity scores. Previous work 
[8,9] demonstrates that individual dose titration results in overall dose reduction while 
maintaining clinical efficacy. Dose titration based on the disease activity is also applied in 
the BEST study, a study which compared different treatment strategies in early-RA.[10] 
Although the tight dose-escalation protocol resulted in the fact that 43 patients (46%) 
received dose escalations, due to permanent monitoring of the disease activity, 28 (67%) 
high dose inflximab patients could tapered down and finally could stop infliximab. So 
titration of the infliximab dose based on disease activity could avoid both over- and 
undertreatment.
Possible benefits of this approach include a substantial reduction in costs and possible 
reduction in dose dependent side effects. The latter could be relevant in light of the 
recently published dose dependant increase in solid and haematological malignancies 
during treatment with monoclonal antiTNF-alpha antibodies.[11]
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Methods
Patients
Patients with RA according to the ACR 1987 revised criteria treated in the Sint 
Maartenskliniek (Nijmegen, The Netherlands) with 5 mg/kg infliximab (irrespective of 
dose frequency) were included in this prospective cohort study.[19] These patients were 
initially treated with 3 mg/kg, but had been subsequently dose escalated to 5 mg/kg based 
on the clinical judgement of the treating physician. Every visit the patients have been 
weighed and  dosed in mg per kg bodyweight, with a maximum allowed deviation of 
+/- 10%
Two other inclusion criteria were used: stable disease activity and stable treatment: 
current high disease activity (DAS28 > 5.1) was not allowed and the infliximab dose or 
interval was not altered within the timeframe of 2 infusions. No other inclusion or 
exclusion criteria were used. Enrolment took place from August to October 2006. 
 
Methods
Retrospective description of the study population
A standardized chart review form was used to collect data on demographics, previous 
medication and clinical benefit of infliximab. Demographic data included age, gender, 
disease duration and rheumatoid factor results. The number of previous DMARDs and 
previous biologicals was also recorded. The retrospective clinical benefit of 3 mg/kg and 5 
mg/kg dose infliximab was recorded by noting DAS28-scores at start of the initial 3 mg/kg 
infliximab therapy,  after 14 weeks 3 mg/kg infliximab therapy, before dose-escalation to 
5 mg/kg, after dose escalation to 5 mg/kg and before DAS28-dose reduction, the start of 
the current study. The DAS28 scores were recorded along with the duration of therapy, the 
percentage of flare before dose-escalation and the response after dose escalation.
Prospective DAS-28 guided dose reduction
After inclusion infliximab dose was decreased to 3 mg/kg; the dosing intervals were 
left unaltered. Treatment with DMARDs or prednisone was allowed and was aimed to 
remain unchanged. Patients were followed for at least three infusion visits by a physician. 
Disease activity was evaluated immediately before each infusion using the Disease 
Activity Score (DAS28).[20] A disease flare was defined based on reversed EULAR (European 
League Against Rheumatism) response criteria as documented previously [8,20]: an 
increase in DAS28 exceeding 1.2 or an increase in DAS28 exceeding 0.6 and a current DAS28 
> 5.1 (high disease activity). Patients were encouraged to contact the investigators if they 
experienced a flare of disease activity between two visits. If a flare persisted more than 1 
infusion, the dose of infliximab was again escalated, and disease activity was measured 
after this rechallenge. Finally, adverse events were assessed at every visit.
The primary end point was defined as the proportion of patients in whom infliximab 
dosages could not be lowered without inducing a persistent (>1 visit) flare of disease 
activity within the timeframe of two lowered dosages of infliximab. No control group was 
In addition to dose titration based on disease activity, data derived from both 
rheumatology and gastro-enterology patients suggest that the determination of serum 
trough concentrations of infliximab and anti-infliximab antibodies may help to optimize 
treatment. Low serum trough levels of infliximab have been associated with reduced 
clinical efficacy.[ 4, 12-15] Furthermore, clinical response in RA decreases rapidly with 
serum infliximab trough levels under 1 mg/l.[15] Of note, in contrast to the lower limit, less 
is known about the upper limit of the therapeutic window. 
The pharmacokinetics of infliximab can be altered by the formation of antichimeric 
antibodies against infliximab (HACA). HACA’s have been found in 8% to 43% of RA patients 
treated with infliximab and have been associated with less efficacy and higher adverse 
event rates.[15-18] Knowledge of the (anti-) infliximab serum-concentrations could 
therefore provide auxiliary information for the decision whether a dose escalation or de-
escalation is necessary.
The aim of the present study is to assess the percentage of RA patients treated with 
infliximab in which dose reduction could be reached without loss of clinical efficacy and 
to confirm the feasibility of disease activity guided infliximab dose adjustment. 
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Results
Patients 
In august 2006 125 patients with RA were being treated with infliximab in the Sint 
Maartenskliniek, of which 20 (16%) were receiving infliximab in a dose of 5 mg/kg. These 
patients were treated for 20 (±14) months with 5 mg/kg infliximab with an infusion 
interval of 6.1 (±1.5) weeks. These 20 patients were selected to participate in this study. 
Two patients dropped out before study start: one patient was switched to rituximab and 
another to adalimumab, both because of longstanding moderate disease activity (DAS28: 
4.42 and 4.34 respectively). Baseline characteristics of the 18 patients in this study are 
listed in table 1. 
Table 1    Baseline characteristics of patients
n = 18
Age (yrs) 53 ± 14
Woman (n,%) 14 (78)
Disease duration (yrs) 11.0 ± 7.1
Previous DMARDs (n) 3.3 ± 1.8
Previous biologicals (n) 0.3 ± 0.6
Rheumatoid factor positive (n,%) 16 (78)
Duration of infliximab therapy (mths) 48.3 ± 14.7 
Duration of 5 mg/kg infliximab therapy (mths) 19 ± 14 
EULAR-responder at week 14 infliximab (%) 65
Flare before dose escalation (%) 56
EULAR-responder after dose escalation (%) 50
Interval infliximab infusions (wks) 6.1 ±1.5
DMARD at baseline (n,%) 16 (89)
  Methotrexate (n,%) 15 (83)
  Dose (mg/week) 14 ± 5
  Azathioprine (n,%) 1 (6)
Prednisone at baseline (n, %) 5 (28)
  Dose (mg/day) 6.5 ± 2.2
Variables are expressed as mean ± SD unless stated otherwise. wks = weeks; mths = months; yrs = years
included in the design, assuming that disease activity would have remained stable 
in all patients when the infliximab dose would have remained stable. 
Measurement of serum infliximab and anti-infliximab antibody 
levels 
Serum samples were collected one hour prior and directly after each infusion, 
for the assessment of serum infliximab and anti-infliximab antibodies. Infliximab- 
and anti-infliximab antibody levels in serum were determined by an enzyme-
linked immunosorbent assay and a radioimmunoassay respectively.[17,21] 
We categorized serum trough levels in low (< 1mg/l), medium (1-5 mg/l) and 
high (> 5 mg/l) levels. In contrast to the lower limit, less information is available 
about the maximum desirable infliximab serum trough level. Therefore, we 
arbitrary choose that serum trough levels above 5 mg/l are high levels, which is 5 
times the minimum serum trough level and 3.3 times the average serum trough 
level (table 3).[22] Previously, Wolbink et al [14] used tertiles to categorize serum 
levels at 14 weeks in low, medium and high levels, also categorizing serum trough 
levels above 5 mg/l as high.
Ethical considerations 
Adjusting the dosage of infliximab treatment guided by the actual disease 
activity was performed as routine clinical care in the Sint Maartenskliniek. 
Approval from the Research Ethics Committee (MREC) was not necessary after 
consultation because DAS28 guided dose adaptation was performed as part of 
usual care.
Statistical analysis
 Descriptive statistics were provided using mean (+/- SD) or median (p25-p75) 
values depending on the (non-) parametric distribution of measured variables. The 
disease activity at study start and at the end of the study was compared using a 
paired T-test. The confidence interval around the point estimate of the percentage of 
patients in whom a flare occurred after dose reduction was calculated as follows: 
incidence rate ± 1.96 * √ (incidence rate * (1- incidence rate) / number of cases). Non-
parametric variables were analyzed using the Wilcoxon’s rank sum test (paired 
samples) and the Mann-Whitney U test (independent samples). 
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Measurement of serum infliximab and anti-infliximab antibody levels
The median serum trough infliximab levels (interquartile range) were before the first 
decreased dose 4.7 (0.48-12) mg/l. After the dose was decreased the infliximab serum trough 
level decreased to 3.1 (0.59-6.2) mg/l and 3.1 (0.17-8.2) mg/l, before the second and third 3 
mg/kg infliximab infusion respectively (table 3). 
Table 3    distribution of infliximab serum trough levels 
Serum infliximab before infusion Before dose 
decrease (visit 1)
After dose 
decrease (visit 3)
Low (<1 mg/l (anti-infliximab antibody positive)) 6 (2) 6 (4)
Intermediate (1-5 mg/l) 3 7
High (>5 mg/l) 9 5
Serum trough infliximab levels showed considerable variation between patients. 
However, the infliximab serum trough levels before dose decrease did not show a Gaussian 
distribution. Most patients had either low or high serum trough levels. 
Detectable anti-infliximab antibodies were found in two and four patients respectively, 
before and after dose decrease. These patients had significant lower serum trough levels 
compared to patients without detectable anti-infliximab antibodies (p<0.005, Mann-
Whitney U test). Infliximab serum trough levels in the one patient with unsuccessful dose 
decrease were high: 12.2 mg/l, 8.7 mg/l and 12.7 mg/l, before the first and second 3 mg/kg 
infliximab infusion and the first 5 mg/kg infusion respectively. In this patient anti-
infliximab antibodies could not be detected.
Figure 1    individual DAS28 course during the study, visit 1, 2 and 3: before first, second and third low dose infusion 
(3mg/kg) respectively.
Retrospective description of the study population
The mean DAS28 in our study population before the start of infliximab was 5.7 (±1.2) In 
the first 14 weeks after the start of 3 mg/kg infliximab  the DAS28 was decreased to 3.9 
(±1.3)  (table 2). After a mean of 27.0 (±16.1) months, dose was escalated to 5 mg/kg. The 
DAS28 before dose escalation was 4.8 (±1.6) and decreased after dose escalation to 3.5 
(±1.1). 
Table 2    retrospective and prospective infliximab doses and DAS-28 scores
Before 
start 
infliximab
At week 14 Before 
dose 
increase
After dose 
increase
Before 
dose 
decrease
After dose 
decrease
Inliximab dose (mg/kg) - 3 3 5 5 3
DAS 28 scores 5.7 (±1.2) 3.9 (±1.3) 4.8 (±1.6) 3.5 (±1.1) 3.2 (±1.6) 3.3 (±1.2)
Prospective DAS-28 guided dose reduction
At dose-reduction study start and at the second and third low infusion, the mean DAS28 
in the infliximab group was 3.2 (± 1.6),  3.2 (± 1.2) and  3.3 (± 1.2) respectively  (table 2, fig 1). 
The difference of DAS between the first and the last visit was not significant (p=0.91). 
The primary end point, defined as the proportion of patients in whom infliximab dosages 
could not be lowered without inducing a persistent (>1 visit) flare of disease activity within 
the timeframe of two lowered dosages of infliximab, was met in one patient (6%, CI 0-17). In 
this patient lowering the infliximab dose resulted in an increase of > 1.2 (DAS28 3.30 to 4.65) 
of DAS28 before the second low dose infusion. This increase sustained until the next infusion 
(DAS28 5.11). After re-challenge with 5 mg/kg infliximab this patient responded again (DAS28 
2.47). Three other patients in the infliximab-group flared at the third visit. One of them had 
to stop infliximab because of a ‘lupus like reaction’. In the other two patients the flare 
subsided spontaneously without medical intervention after the next visit. All other patients 
remained in stable disease activity after lowering the dose of infliximab. The mean DAS28 
in patients without a flare was 3.32 (± 1.1), 3.18 (± 1.1) and 3.04 (± 1.1) before the first, second 
and third low dose of infliximab. Individual components of the DAS28 in patients without a 
flare showed the following pattern: median (p25-p75) values at visits 1, 2 and 3 respectively 
were 1.0 (0-3), 1.0 (0-2) and 1.0 (0-3) (swollen joint count), 1.0 (0-2), 0.0 (0-3) and 1.0 (0-2) 
(tender joint count), 23.0 (8-40), 25.0 (11-33) and 16.0 (9-31) (ESR), 27 (18-40), 22 (10-42) and 29 
(20-39) (VAS).
None of the patients contacted the investigators between visits because of experienced 
increased disease activity or adverse effects. In 2 patients side effects (nausea and 
alopecia) led to a dose decrease of concomitant treatment with methotrexate).
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In conclusion, our study indicates that a dose of 5 mg/kg infliximab could be lowered in 
the majority of RA patients without persistent increase of disease activity measured with 
the DAS28 in routine clinical practice. Individual dose titration of infliximab should be 
considered in daily clinical care to reach the best individual dose, thus avoiding dose 
dependant side effects and optimizing cost effectiveness. Further investigation into the 
added value of the determination of serum infliximab-concentrations is necessary to 
determine when therapeutic drug monitoring may help to optimise this treatment.
Discussion
Our study demonstrates that infliximab in a dose of 5 mg/kg could be down titrated to 
lower infliximab doses (3 mg/kg) in the great majority of RA patients without increase of 
disease activity and that this approach is feasible in clinical practice.
Although the number of patients in the present study is limited and no control group is 
present, this does not necessarily hamper internal validity. Firstly, a higher number of 
patients would only increase precision, but at present even the most conservative estimate 
(i.e. higher border of confidence interval) of percentage of patients shows that most 
patients can be lowered safely without increase of disease activity. Furthermore, the best 
case scenario in a control group would be stable disease activity in all patients (it seems 
very unlikely that patients would improve spontaneously after being stable for a long 
time). With the therefore conservative assumption of stable disease activity, the 
percentage of patients that can be down titrated is never overestimated. 
There are several possible explanations for the fact that infliximab could be lowered in 
almost all patients. The first possibility is that infliximab serum trough levels after de-
escalation are still above the minimal effective serum level. This seemed to be the case in 
the majority of patients in our study. This finding is interesting, as in most of our patients 
a documented high disease activity was present before dose-escalation and clinical 
response was again achieved in these patients. Although this seems contradictory, the 
observed patterns could be explained by either regression to the mean [7] or by a temporary 
need for higher infliximab doses. 
Another possible explanation for our findings could be already subtherapeutical 
infliximab serum trough levels before dose reduction. In these patients, dose de-escalation 
of subtherapeutical doses should of course be successful. Low serum trough levels could 
be caused by the production of anti-infliximab antibodies or an increased infliximab 
clearance, and both patterns were seen in a subset of our patients. Finally it could be 
postulated that some patients have developed (secondary) resistance to antiTNF-alpha 
agents without antibodies or low serum levels of infliximab.
A few aspects regarding the generalisability of our study should be noted. Firstly, the 
liberal inclusion criteria enhanced external validity of the study. Furthermore, the studied 
subjects were included from a source population that does not differ much from other 
infliximab cohorts: both the drug survival of all patients treated with infliximab in our 
cohort [9,23] and the percentage of patients that receive higher doses are lower than other 
biologic DMARDs registers.[6,7] However, these more conservative characteristics of the 
source population would only result in an underestimation of percentage of RA patients 
treated with high dose infliximab that could be down titrated.
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Abstract
Objective
This study in patients with rheumatoid arthritis (RA) treated with infliximab describes 
prospectively the course of (anti)infliximab levels within an infusioncycle to assess at 
what moment patients develop low/no infliximab trough levels and/or detectable anti-
infliximablevels. 
Methods
Infliximab treated RA patients were included in this descriptive open-label cohort 
study. During one infusioncycle (anti-)infliximab levels and disease activity scores were 
assessed just before and one hour after infusion, and subsequently at 50%, 75% and at the 
end of the infusioncycle (pre-infusion).
Results
27 patients were included. The median infliximab levels decreased from 77.0 mg/l 
(p25-p75: 65-89) one hour after the infusion to pre-infusion levels of 0.0 mg/l (p25-p75: 
0.0-3.1). In 7 (26%) patients pre-infusion anti-infliximab antibodies were detected; these 
antibodies were already present halfway through the infusioncycle in 5 of the 7 individuals. 
Patients with detectable pre-infusion anti-infliximab antibodies have significantly more 
often low/no infliximablevels (< 1 mg/l) halfway trough the infusioncyle (in 5/7 patients) 
compared to patients without detectable pre-infusion anti-infliximab antibodies (0/20 
patients, p<0.001). The mean pre-infusion DAS28-score (3.4 ± 1.1) of all patients was 
significantly (p=0.03) higher than the DAS28 halfway through the infusion (3.0 ± 1.1).  
Conclusion
Most anti-infliximab forming patients have detectable anti-infliximab antibodies 
halfway through an infusioncycle, which implies that these patients are exposed to 
nontherapeutical infliximablevels during more than halve of their infusion cycle. As none 
of the patients without anti-infliximab antibodies had no/low-infliximab levels halfway 
through the infusioncycle, the presence of pre-infusion anti-infliximab antibodies seems 
a sensitive and specific predictor for no/low infliximab-levels 
Introduction
The tumour necrosis factor (TNF) antagonists infliximab, adalimumab and etanercept 
have been proven to reduce disease activity and suppress radiographic joint damage in 
patients with recent onset [1-3] and established rheumatoid arthritis (RA).[4-6] About 40-
60% and 20-40% of the patients met the American College of Rheumatology (ACR) 50% 
and 70% improvement criteria respectively [7], compared to placebo improvement 
percentages of 7-11% (ACR50) and 2-4% (ACR70). However, these results also implicate that 
up to 60% of patients with RA do not reach the clinical relevant 50% improvement. 
Therefore, non-responders (both primary as secondary non-responders) should be 
identified as early as possible. Firstly, a shorter period of high disease activity minimises 
chances of joint destruction. [8,9] Also treatment with TNF antagonist is associated with 
considerable costs. Finally there is ongoing debate on their safety and possible dose related 
adverse effects.[10-12]
Because valid prediction models are not available at this point, close monitoring of 
individual disease activity and adapting the treatment (dose) is the first available step to 
improve the efficacy of RA-therapy [13-17]. However, although disease activity guided 
treatment is a valuable instrument, this strategy cannot distinguish between patients 
who improve through the pharmacological effect of infliximab or patients who’s 
improvement in disease activity is caused by comedication, expectation bias or more 
importantly the natural course of the disease (regression to the mean) [18] 
Pharmacokinetic data with infliximab indeed show that some patients achieve 
improvement and low disease activity during infliximabtherapy, although this response 
could most likely not be attributed to infliximab as these patients had no- or low-infliximab 
trough levels. These reduced levels could partially be explained by the formation of human 
antichimeric antibodies against infliximab (HACAs) which occurs in 8% to 43% of the RA 
patients. [19-22]. The formation of antibodies against infliximab has been associated with 
altered infliximab pharmacokinetics and reduced serum infliximab concentrations over 
time in patients with RA [23].
Clinically, it is relevant to know whether patients with serum trough anti-infliximab 
antibodies also have these antibodies present early in a treatment cycle or whether they 
appear only at the end of a treatment cycle. Patients with “early” anti-infliximab detectable 
antibody formation would have a long window wit nontherapeutical levels of infliximab. 
The alternative scenario, appearance of HACA’s predominately at the end of the infusion 
cycle would of course be less important as adequate infliximab levels would be present 
during the majority of time between infusions. However, until now, it is unknown what 
the relationship is between trough anti-infliximab antibody levels and (anti-)infliximab 
antibody throughout the treatment cycle.
This study describes therefore prospectively the course of (anti)infliximab levels and 
disease activity between an infusion cycle of two infusions in patients with rheumatoid 
arthritis. 
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Results
Twenty-seven patients were enrolled in the study; their demographic and clinical data 
at baseline are summarized in table 1.
Table 1    Baseline characteristics of patients
n = 27
Age (yrs) 61.6 ± 10.0
Woman (n,%) 15 (56)
Median disease duration (yrs, p25-p75) 11.2 (4.2- 17.4)
Median number of previous DMARDs (n) 2.5 (2.0- 3.3)
Previously treated with another biological (n, %) 3 (11%)
Rheumatoid factor positive (n,%) 21 (78)
Duration of infliximab therapy (yrs) 3.7 ± 2.3
Interval infliximab infusions (wks) 6.8 ± 2.0
Disease Activity at baseline
  Remission (n,%)  7 (26)
  Low disease activity (n,%)  6 (22)
  Moderate disease activity (n,%) 11 (41)
  High disease activity (n,%)   3 (11)
DMARD at baseline (n,%) 23 (85)
  Methotrexate (n,%) 17 (63)
  Dose (mg/week) 16.8  ± 5.5
  Azathioprine (n,%) 4 (15%)
Prednisone at baseline (n, %) 5 (19%)
  Dose (mg/day) 5.8  ± 1.8
Variables are expressed as mean ± SD unless stated otherwise. wks = weeks; mths = months; yrs = years
 
(Anti) Infliximab concentrations 
Table 2 shows the median infliximab levels and the decrease of infliximab serum trough 
levels during the infusioncycle. In 7 (26%) patients anti-infliximab antibodies were 
detected just prior to the next infusion. These antibodies were already present at 50% of 
the infusioncycle in 5 of the 7 individuals. A concomitant DMARD was used in 6 (86%) of 
the patients with detectable anti-infliximab antibodies and in 17 (85%) of patients without 
anti-infliximab antibodies.  Remission or low disease activity was present in 4(57%) of the 
patients with detectable anti-infliximab antibodies compared to 9(45%) patients without 
detectable antibodies. 
Methods
Patients
Patients with RA, according to the ACR 1987 revised criteria, treated at the Sint 
Maartenskliniek (Nijmegen, The Netherlands) for at least 3 months with 3 mg/kg infliximab 
(irrespective of dose frequency) were included in this observational, descriptive open-
label pharmacokinetic cohort study.[24] No other inclusion or exclusion criteria were 
used. In the Sint Maartenskliniek all RA patients receive 3 mg/kg infliximab, with dose 
intervals adjusted to patient’s disease activity. When a patient does not reach low disease 
activity on 3 mg/kg/4 wks the patient is switched to another DMARD or biological.
Study protocol
Patients were enrolled between February and April 2008. Ethical approval was obtained 
from the Ethics Committee Nijmegen-Arnhem and all participants gave written informed 
consent before screening. A standardized chart review form was used to collect data on 
demographics, previous medication and clinical benefit of infliximab.
Pharmacokinetic and pharmacodynamic assessment
Patients were assessed during one treatmentcycle. (Anti-) infliximab levels were 
assessed at five time-points: one hour prior to the first infusion, one hour after the 
infusion, at 50% and 75% of the infusioncycle, and just before the next infusion. The 
Disease Activity Score (DAS28) was assessed at the same time points excluding the post 
infusion time point.
Infliximab- and anti-infliximab antibody levels in serum were determined by an 
enzyme-linked immunosorbent assay and a radioimmunoassay respectively.[21,25]. We 
categorized serum trough levels in low (< 1 mg/l), medium (1-5 mg/l) and high (> 5 mg/l) 
levels. In contrast to the lower limit (1 mg/l), less information is available about the 
maximum desirable infliximab serum trough level. Therefore, we arbitrary choose that 
serum trough levels above 5 mg/l are high levels, which is 5 times the minimum serum 
trough level and 3.3 times the average serum trough level.[26] Previously, Wolbink et al 
[25] used tertiles to categorize serum levels at 14 weeks in low, medium and high levels, 
also categorizing serum trough levels above 5 mg/l as high.
Statistical analysis
Descriptive statistics were provided using mean (+/- SD) or median (p25-p75) values 
depending on the (non-) parametric distribution of the variables. We used Mantel-
Haenszel Chi-square-tests to evaluate differences in proportions, and Student’s t-tests to 
evaluate differences in means. The disease activities before the next infusion and halfway 
through the infusion were compared using a paired T-test. Non-parametric variables were 
analyzed using the two-sample paired sign test.
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Figure 1    Serum trough infliximab levels during the infusioncycle in antibody-forming and non-anti-body forming 
RA patients
Table 3    Disease activity (measured by the DAS28) and EULAR-disease activity classification percentages during one 
infusioncycle.
Prior to 
infusion
50% of the 
infusioncycle
75% of the 
infusioncycle
100% of the 
infusioncycle
Mean DAS28 (± SD) 3.3 (± 1.1) 3.0 (± 1.0) 3.4 (± 1.1) 3.4 (± 1.1)
Patients in remission (n, %) 7 (26%) 10 (37%) 6 (22%) 8 (30%)
Patients with low disease activity 
(n, %)
6 (22 %) 6 (22%) 6 (22%) 3 (11%)
Patients with moderate disease 
activity (n, %)
11 (41%) 11 (41%) 14 (52%) 15 (56%)
Patients with high disease activity 
(n, %)
3 (11%) 0 (0%) 1 (4%) 1 (4%)
Table 2    Median and distribution of infliximab serum trough levels
Median infliximablevels Prior to 
infusion
1 hour after 
infusion
50% of the 
infusioncycle
75% of the 
infusioncycle
100% of the 
infusioncycle
Median infliximab levels  
(p25-p75)
0.6 
(0.0 - 3.1)
77.0 
(65-89)
5.9 
(1.5-13)
2.7 
(0.2-5.7)
0.0 
(0.0-3.1).
Distribution of 
infliximablevels
Patients with low 
infliximablevels (<1 mg/l )
18 0 5 8 15
Patients with intermediate 
infliximablevels (1-5 mg/l)
5 0 5 9 8
Patients with high 
infliximablevels (>5 mg/l)
4 27 17 10 4
HACA positive patients 7 0 5 6 7
Figure 1 depicts the elimination of infliximab during a single infusioncycle categorized 
as patients with and without detectable anti-infliximab antibodies. At 50% of the 
infusioncycle 5/7 (71%) of patients with HACAs at pre-infusion had low infliximab serum 
levels (< 1 mg/l) which was significantly more frequent compared to 0/20 of the non-
antibody forming patients (p<0.001).
Course of the disease activity between two infusions
Disease activity (DAS28) and EULAR-disease activity classification percentages are 
shown in table 3. Disease activity was significantly (p=0.03) higher prior to the next 
infusion than the disease activity halfway through the infusion. At the end of the 
infusioncycle 11 (41%) patients showed low disease activity or remission, which tended to 
be lower compared to the 16 (59%) patients with low disease activity or remission halfway 
through the infusioncycle (p=0.06).
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It should be noted  that the design of this study is not suitable to draw conclusions 
about the correlation between pharmacokinetic- ((anti)-infliximablevels) and the 
pharmacodynamic- (disease activity) parameters. Patients were treated according to the 
local disease activity guided protocol, which automatically excluded the majority of non-
responders in this observational cohort. This could lead to a selected study population, in 
which pharmacokinetic parameters could not be correlated with non-response.
In conclusion, this study demonstrates that a substantial proportion of RA-patients 
treated with infliximab are already exposed to no/low-infliximablevels during more than 
halve of their infusion cycle. The presence of pre-infusion anti-infliximab antibodies could 
be used as a sensitive and specific predictor for no/low infliximab-levels halfway the 
infusioncycle. 
Discussion
Our results indicate that anti-infliximab antibodies are frequently found in patients 
with low and moderate disease activity and that these antibodies are already detectable 
in most of these patients halfway through an infusioncycle. This implies that the presence 
of anti-infliximab antibodies at the end of an infusioncycle seems a good predictor for low 
infliximab-levels throughout most of the infusioncycle. In addition, we observed that 
measuring disease activity just before a next infliximab infusion is not fully representative 
for the disease activity in the preceding infusioncycle: the disease activity was higher and 
EULAR responses were less favourable just before a next infusioncycle compared to 
halfway through the infusioncycle.
This study has three significant clinical implications. First, we found that in patients 
with low infliximab trough levels, the presence of serum trough anti-infliximab anti-
bodies could be a specific and sensitive indicator for absence of serum infliximab level 
during at least half of the infusioncycle. 
Secondly, our finding that one fifth of the patients treated with infliximab have already 
non/low infliximab-levels halfway through the infusion implicates that either these 
patients benefit from a pulse treatment with infliximab or that they do not benefit from 
infliximab at all. Future research would be necessary to clarify this question, for example 
by stopping infliximab therapy in patients with non-detectable infliximab-levels.
Finally, the increase in disease activity at the end of the infusioncycle could lead to an 
underestimation of the effect of infliximab when disease activity is only measured just 
before infusion. These finding implicates on population level that observational studies 
comparing subcutaneous- (etanercept, adalimumab) and intravenous- (infliximab, 
abatacept and tocilizumab) antirheumatic agents should be interpreted with caution 
when disease activity for intravenous agents is conveniently assessed at the end of an 
infusioncycle while disease activity in other drugs is often assessed on different moments 
during a dosing interval. This could theoretically lead to an underestimation of the effect 
of intravenous antirheumatic agents compared to subcutaneous agents.
Underestimation of the disease activity at the end of an infusion cycle, is less relevant 
in individuals, as anti-rheumatic drugs should keep disease activity during the complete 
treatment period at a stable, low level, in order to keep structural damage to a minimum 
since fluctuations in disease activity are directly related to changes in radiologic 
progression. [27]
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Abstract
Objective
In this explorative study, the possible additional value of serum (anti-) infliximab levels 
for early prediction of dose dependant (non-)response and assessment of unnecessary 
treatment was studied in disease activity guided RA patients treated with infliximab.
Methods
All RA patients starting infliximab where enrolled in an inception cohort, whereas 
patients on infliximab maintenance therapy were included in a follow up cohort. In 
starters and patients with high disease activity, sensitivity and specificity for good EULAR 
response after 6 months (inception cohort) or the combination of low disease activity and 
DAS28 improvement of > 0.6 after change of therapy (follow up cohort) was calculated 
using ROC curves while aiming for maximum sensitivity. In patients with low disease 
activity the number of patients with no/low infliximab trough levels was assessed.
Results
The combination of DAS286weeks > 4.5 and infliximab serum trough levels < 2.5 mg/L 
was a fair predictor for good EULAR response after 6 months (sensitivity 100%/specificity 
51%), but improvement after dose increase could not be predicted. 14 of 38 patients with 
longstanding low disease activity had suspected too low infliximablevels (< 1 mg/L) of 
whom 10 (26%) had detectable anti-infliximab antibodies.
Conclusion
Infliximab trough levels can be used to predict response to infliximab, but seem not 
useful to predict response to dose increase. Low/no infliximab trough levels can be 
detected in a substantial number of patients with longstanding low disease activity, 
suggesting that low disease activity was unrelated to the - most likely ineffective - 
infliximab treatment.
Introduction
Infliximab, a chimeric (human-mouse) monoclonal antibody to human tumor necrosis 
factor-a (TNF-a), gives rapid, sustained clinical response, retards radiographic progression 
and improves functional status in patients with rheumatoid arthritis (RA).[1,2,3]. In the 
two pivotal RCTs (ATTRACT and ASPIRE) a major clinical response (American College of 
Rheumatology, ACR50% response) was found in respectively 21-46% of the patients using 
3 mg/kg infliximab every 8 weeks combined with methotrexate, a significantly higher 
proportion compared to methotrexate alone (ACR50% response 8-32% respectively) [1,3]. 
In both studies low doses tended to be somewhat less effective than higher doses, although 
this difference was only significant in the ATTRACT study with respect to the ACR50 
responders and not for the primary endpoint (ACR20). Based on these studies, at most 17% 
of the patients seems to benefit from doses >3 mg/kg/8 weeks.
This suggests that patients that do not reach low disease activity on infliximab could 
be categorized in two subgroups: one smaller subgroup who would benefit from a dose 
escalation and a larger subgroup who would not. Patients that do reach low disease 
activity after infliximab can also conceptually be divided in three subgroups: (1) patients 
receiving an adequate dose, (2) patients who would also have had responded on a lower 
dose and thus are being overtreated and (3) patients who’s low disease activity was not 
caused by infliximab therapy but resulted from other factors like expectation bias (placebo 
response sensu strictu), regression to the mean or co-medication.[4,5].
Although the triad of close monitoring of disease activity, setting goals for low disease 
activity and adapting the treatment (dose) accordingly improves the efficacy of RA-
therapy considerably [6-10], disease activity guided dosing can not easily, rapidly and 
efficiently distinguish between the two subcategories of non-responders and three 
categories of patients with low disease activity as described above. In patients with low 
disease activity, disease activity guided treatment cannot differentiate between 
responders with therapeutical doses, responders with supra-therapeutical doses or 
patients low disease activity due to other factors than infliximab, without dose reduction 
strategies that take time and can result in disease flares. In patients with moderate or 
high disease activity, non-response due to subtherapeutical dosing remains undetected 
unless costly and time consuming dose escalation strategies are employed. Thus, besides 
the measurement of the (change in) disease activity, a predictive measure that could be 
used in patients were there exist pre test uncertainty about the outcome of dose changes 
would be helpful.
Pharmacokinetic data of infliximab could be an instrument to optimize disease activity 
guided dosing by early identification of the above-mentioned subgroups of patients and 
predicting the success rate of dose-adjustments. Infliximab serum trough levels are 
measurable, are associated with therapeutic effect, and have a large interindividual 
variability thereby fulfilling the necessary conditions for effective therapeutic drug 
monitoring (TDM) [11,12]. Of note, this variability in the pharmacokinetics of infliximab 
could partially be explained by the formation of human anti-chimeric antibodies against 
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Patients and Methods
Patients
All patients with RA, according to the ACR 1987 revised criteria, treated at the Sint 
Maartenskliniek (Nijmegen, The Netherlands) with infliximab (irrespective of dose or 
frequency) were included in this prospective study [19]. Patients were enrolled between 
February 2007 and May 2008. All RA patients who started infliximab during the observation 
period were enrolled in an inception cohort, whereas patients who were already on 
infliximab at study inclusion were included in a follow up cohort. The infliximab starters 
in the inception cohort who completed the induction phase (first 14 weeks of infliximab 
use), were subsequently enrolled in the follow up cohort. No other inclusion or exclusion 
criteria were used. The observation period started the day of inclusion and was censored 
on the 24th of September 2008, or sooner when treatment was discontinued for any 
reason, or when the patient stopped attending.
Figure 1    Treatment protocol
infliximab (HACAs) which occurs in 8% to 43% of the RA patients. [13-15], as antibodies to 
infliximab have been associated with altered infliximab pharmacokinetics and reduced 
serum infliximab concentrations in patients with RA [16]. 
Although several cross sectional publications suggest that assessment of (anti-)
infliximab serum trough levels may be useful for optimization of infliximab treatment 
[13,15,17,18], no prospective study so far has attempted to explore the test characteristics of 
infliximab and anti-infliximab serum trough levels in different scenario’s in a cohort of 
patients being treated based on disease activity. Therefore, we have set up a prospective 
cohort of RA-patients treated with infliximab based on disease activity scores. In this 
cohort the added value of measuring infliximab serum trough levels above disease activity 
guided treatment was studied
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Ethical considerations 
Approval from the Research Ethics Committee (MREC) was sought for. The committee 
decided that this approval was not necessary because DAS28 guided dose adaptation was 
performed as usual care for all patients meeting the requirements of the Dutch legislation 
and no extra venous puncture was necessary.
Statistical analysis
Descriptive statistics were provided using mean (+/- SD) or median (p25-p75) values 
depending on the (non-) parametric distribution of measured variables. We used Mantel-
Haenszel Chi-square-tests to evaluate differences in proportions, and Student’s t-tests to 
evaluate differences in means. ROC curves (receiving operating characteristic) were used 
to assess the optimum trade-off between sensitivity and specificity for cut-offs for 
predicting response using DAS28-scores and infliximab serum trough levels as possible 
predictor. 
Treatment protocol
All patients that started infliximab fulfilled the Dutch criteria for reimbursement of 
anti-TNFα therapy: 1) moderate or high disease activity (DAS28 > 3.2) and 2) having failed 
at least two DMARDs including methotrexate (MTX) in an optimal dose up to 25 mg per 
week with folic acid supplementation. The treatment goal in our local treatment protocol 
(figure 1) was to obtain low disease activity (DAS28 ≤ 3.2). Patients started with 3 mg/kg 
infliximab at weeks 0, 2 and 6 and subsequently every 8 weeks thereafter. Treatment 
decisions were based on a DAS28 guided treatment protocol, which describes a number of 
subsequent steps for patients with persistent high disease activity (defined as two 
consecutive DAS28 scores > 3.2) or longstanding (> 6 months) remission (DAS28< 2.6). This 
DAS28 guided treatment protocol consisted of the following main decisions: 
1 After induction (inception cohort at 14 weeks)
In patients who did not reach a DAS28 ≤ 3.2, although they had at least partial response 
(defined as a DAS28 decrease of at least 0.6 units, being the measurement error) after 
either 6 or 14 weeks, the protocol recommended to decrease the infusion interval to 4 
weeks. In patients that did not reach at least partial response after 6 or 14 weeks, the 
protocol recommended to stop infliximab therapy.
 2 Maintenance phase (follow up cohort, > 14 weeks therapy)
If a patient had DAS28 scores > 3.2 during two consecutive cycles, the protocol 
recommended to decrease the infusion interval to 4 weeks. When after interval decrease 
the DAS28 score remained above 3.2 after two consecutive infusions the protocol advised to 
stop infliximab therapy. When low disease activity (DAS28 < 3.2) was however reached after 
dose escalation, patients maintained their higher dose.
If the disease consistently remained in remission (> 6 months a DAS28 score < 2.6), the 
infusion interval was increased every two infusion cycles with two weeks. When patients 
retained in remission after two infusions of infliximab with an interval of 12 weeks the 
infliximab was stopped.
Outcomes
Primary outcome measure in the inception cohort was fulfilment of good EULAR 
response criteria [20] 6 months after infliximab start, which requires both a DAS28 score 
≤ 3.2 and a decrease in DAS28 >1.2. As patients in the follow up cohort had already shown 
initial response, patients with an infusion interval decrease should reach DAS28 score of 
≤ 3.2 and obtain an additional improvement in DAS28 >0.6 after two consecutive infusions. 
Infliximab- and anti-infliximab antibody levels in serum were determined by an enzyme-
linked immunosorbent assay and a radioimmunoassay respectively [11, 15-20].These assays 
are inexpensive and readily accessible (Sanquin Research, Amsterdam, The Netherlands).
The following baseline data were recorded: demographic variables, year of disease 
onset, previous and concomitant DMARD treatment and systemic corticosteroid and 
methotrexate dosage. At inclusion and at each follow-up visit the dose of administered 
infliximab, adverse effects and co-medication was registered. Trained and calibrated 
research nurses assessed the DAS28 of the patients before each infliximab infusion.
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patients with DAS282 weeks > 5.0 obtained a good EULAR response whereas 17 (39%) of the 44 
patients with DAS282 weeks < 5.0 had a good EULAR response at 6 months. Infliximab serum 
trough levels were also associated with efficacy, as responding patients tended to have 
higher infliximab serum trough levels (23.4 mg/L (± 20.8)) compared to non- or partially 
responding patients (16.0 mg/L (± 10.4); p=0.06). The decrease in disease activity between 
baseline and 2 weeks was not associated with EULAR response at 6 months.
Figure 2    Study flow diagram of the inception cohort
Figure 3    ROC curve for the EULAR good response after 6 months versus the DAS28 score at 2 weeks (AUC: 0.70: 
95%-BI: 0.55-0.84) and after 6 weeks (AUC: 0.80: 95%-BI:0.67-0.92 ).
Results
Inception cohort: baseline
57 consecutive RA patients starting with infliximab therapy were included. Baseline 
demographic and clinical data at baseline are summarized in table 1. Figure 2 shows the 
patient disposition during the study. After 6 months, 16 (28%, CI 12-44%) patients reached 
good EULAR response. None of the baseline variables were significantly associated with 
good EULAR response.
Table 1    Baseline characteristics of patients
Inception cohort  
n = 57
Follow up cohort 
n = 163
Age (yrs, mean ± sd) 57 ± 12 58 ± 12
Woman (n,%) 36 (63) 113 (69)
Co-morbidity (n, %) 24 (42) 70 (43)
Median disease duration (yrs, p25-p75) 6.1 (2.1-16) 9.1 (4.1-15)
Onset RA, (months, mean ± sd) 50 ± 14 50 ± 16
Rheumatoid factor positive (n,%) 44 (79) 126 (77)
Anti-CCP positive 36 (63) 127 (78)
DAS28 at baseline, mean (sd) 5.0 (1.0) 5.2 (1.2)
28 SJC at baseline, median (p25-p75) 7 (3-9) 7 (5-12)
28 TJC at baseline, median (p25-p75) 5 (1-10) 6.5 (2-13)
ESR (mm/hr) at baseline, median (p25-p75) 32 (16-54) 30 (14-44)
Patient global assessment at baseline, mean (sd) 47 (24) 53 (24)
Median number of previous DMARDs (n) 3 (2- 3) 3 (2- 4)
Previously treated with another biological (n, %) 7 (13) 19 (12)
Concurrent corticosteroids (n, %) 16 (28) 25 (15)
Corticosteroid dosage (median p25-p75) 10 (6.3-10) 8.0 (5.0-10)
DMARD at baseline (n,%) 39 (71)  126 (77)
  Methotrexate (n,%) 32 (59) 106 (65)
  Dose (mg/week, median p25-p75) 15 (12-25) 15 (10-16)
Concurrent non-MTX, n (%) 7 (13) 23 (14)
Receiving > 1 current DMARD, n (%) 0 (0) 2 (0)
Inception cohort: 2nd infusion at 2 weeks
The DAS28 was already after 2 weeks significantly lower in patients with a good EULAR 
response after 6 months (DAS282 weeks: 3.5 (±0.8)) compared to patients without a moderate 
or without good EULAR response (DAS282 weeks: 4.3 (±1.1); p=0.01). Figure 3 shows the ROC 
curve for good EULAR response after 6 months in relation to the DAS28 score at 2 and 6 
weeks. At a DAS28 score of 5.0 the sensitivity was 100%; implicating that none of the 12 
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In 13 (25%) patients neither a partial response after 6 weeks nor a good EULAR response 
was observed after 14 weeks. As a consequence, the protocol recommended to stop 
infliximab. In 4 (31%) of these 13 patients the physicians acted conform this recommendation 
and stopped infliximab therapy. None of the 9 patients who still received infliximab 
despite insufficient response attained good EULAR response at 6 months.
 27 (52%) patients showed partial response after 6 or 14 weeks and were therefore 
recommended to receive infliximab with shortened infusion interval. The attending 
physician followed this advise in 7/27 (26%) patients. One of these 7 patients (14%) reached 
good EULAR response after another two infusion intervals, a comparable proportion of 
the 3/19 patients (15%) with an unaltered infusion interval
Follow up cohort: patient and infusion characteristics
The follow up cohort consisted of 163 patients: 109 patients who were already treated 
with infliximab at study start and 54 patients who crossed over from the inception cohort. 
The characteristics of these patients are depicted in table 1. These 163 patients received 
1470 infliximab infusions during the observational period with a median dosing interval 
of 6 (p25-p75: 4-8) weeks. According to the protocol, in 1280/ 1470 infusions, no 
recommendations were made to change the pharmacotherapy.
Follow up cohort: recommendation to decrease dose interval 
In 81 visits in these 163 patients the physician was recommended to decrease the 
infliximab dose interval from 8 to 4 weeks, as the DAS28 from two previous infliximab 
infusions was > 3.2 and treatment schedule with infliximab was every 8 weeks. This 
recommendation was followed in 34 (42%) of the cases (table 3). Physicians seemed to 
comply better to dose adjustment recommendations in patients with higher DAS28 scores, 
as DAS28 before the dose decrease was significantly lower (4.1 ± 0.7) in the 47 patients who 
finally did not receive a dose interval decrease, compared to the 34 patients (4.7 ± 0.8, 
p<0.01) who did receive a decreased interval. 
Table 3    Treatment recommendations within the follow cohort, compliance to the recommendations and responses 
for the different options
Recommendation to the physician Compliance of the 
physician to the 
recommendation
Number of 
patients
response1)
Advise to stop therapy (n=56) Yes 13 NA
No 43 13 (16%)
Advise to decrease infusion interval 
(n=81)
Yes 34 11 (32%)
No 47 15 (32%)
1) :  Response = DAS28 ≤ 3.2 and improvement 
Inception cohort: 3rd infusion at 6 weeks
Patients with good EULAR response after 6 months had already after 6 weeks a 
significantly lower DAS28 (2.9 ± 0.9) compared to patients without good EULAR response 
(4.1 ± 1.0; p< 0.01). The ROC curve (figure 3) for good EULAR response in relation to the 
DAS28 score indicated that none of the 15 (0%) patients with DAS286 weeks > 4.5 obtained a 
good EULAR response whereas 24 (60%) of the 40 patients with DAS286weeks < 4.5 had no 
good EULAR response after 6 months. Table 2 shows the 2x2 table for these test results 
(sensitivity: 100%, specificity: 38%, PPV: 40%, NPV: 100%). Infliximab serum trough levels 
after 6 weeks tended to be higher in responding patients (12.3 mg/L (± 6.1)) compared to 
non-responding patients (9.0 mg/L (± 6.8); p=0.09). All patients with infliximab serum 
trough levels < 2.5 mg/mL (n=9) did not attain infliximab response, while 16 of 46 patients 
with infliximab serum trough levels > 2.5 reached good EULAR-response (sensitivity: 100%, 
specificity: 23%, PPV: 35%, NPV: 100%). The combination of disease activity and infliximab 
levels showed that 20 of 55 (36%) patients had either DAS286 weeks > 4.5 and/or infliximab 
serum trough levels <2.5 mg/L. Furthermore all these patients did not respond (table 2: 
sensitivity: 100%, specificity: 51%, PPV: 46% and NPV:100%). The decrease in DAS28 was 
not useful for prediction of 6 months EULAR good response. 
Table 2    2 x 2 table for prediction of EULAR-response after 6 months versus DAS28 score at 6 weeks (left) and versus 
DAS28 score and/or infliximab serum trough levels at 6 weeks (right)
 
DAS28 response 
(after 6 months)
DAS28 response 
(after 6 months)
Good Non/
moderate
Good Non/
moderate
DAS28 < 4.5 16 (29%)a 24 (44%)b DAS28 < 4.5 and 
infliximab trough 
level > 2.5 mg/L
16 (29%)a 19 (35%)b
DAS28 > 4.5 0 (0%)c 15 (27%)d DAS28 > 4.5 and/or 
infliximab trough 
level < 2.5 mg/L
0 (0%)c 20 (36%)d
Sensitivity = a/(a+c) 100 % Sensitivity 100 %
Specificity = d/(b+d) 38 % Specificity 51 %
PPV (positive predictive value) = a/(a+b) 40% PPV 46%
NPV (negative predictive value) = d/(c+d) 100 % NPV 100 %
Inception cohort: 4th infusion at 14 weeks 
Disease status and treatment at week 14 is depicted in figure 2. The infliximab treatment 
of patients with a good EULAR response (12/54 (22%)) remained unaltered after 14 weeks. 
Eight of these 12 patients (68%) maintained the good EULAR response after 6 months. 
However, in 4 of these 8 patients (50%) low infliximab levels (< 1 mg/L) were detected after 
14 weeks, in 2 of 4 patients attributable to the presence of anti-infliximab antibodies.
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Discussion
The results of this study show two clinical important findings: (1) Therapeutic drug 
monitoring of (anti)infliximab serum trough levels combined with disease activity guided 
dosing seems to have added value above disease activity guided dosing alone at two 
occasions: after 6 weeks to specifically identify non-good responders at 6 months and 
after longstanding therapy in patients with low disease activity to detect patients with 
possible nontherapeutical or supratherapeutical infliximab levels. (2) The efficacy of 
decreasing infliximab infusion intervals in patients with moderate/high disease activity 
seems very modest to non-existent compared to treatment with unaltered doses, 
implicating that switching to another anti-TNF agent or biological is most likely more 
effective. 
Although previous studies in RA identified a variety of variables (gender, smoking, 
disability, NSAID- and MTX-use, RF and anti-CCP-levels), to predict the response to 
infliximab therapy, none of these variables were consistently related to treatment response 
and correlation coefficients were low. [21-24]. In accordance to literature, in this study any 
association between baseline variables and low disease activity after 6 months was also 
absent.
However, we found that the combination of either a DAS28 score of > 4.5 and/or 
infliximab serum trough levels <2.5 mg/L 6 weeks after initiation of therapy was a fair 
predictor (sensitivity: 100%, negative predictive value 100%) for achieving low disease 
activity, with also acceptable specificity (51%). As 36% of the patients starting infliximab 
fulfilled this criterium (50% of the non responders), these patients could potentially be 
switched to another therapy after 6 weeks. Identifying non-responding patients early 
enables the patient to get alternative effective treatment and increases the cost 
effectiveness of the treatment. These findings should however first be validated in another 
cohort of patients with RA treated with infliximab.
The second scenario in which therapeutic drug monitoring could have additional value 
is in patients with longstanding (>6 months) low disease activity, as 37% of them had low 
and probably nontherapeutical infliximab levels, of whom 26% had detectable anti-
infliximab antibodies. This suggests that these patients have an adequate control of their 
disease activity, which could not be attributed to infliximab but to other factors (e.g. due 
to only temporal necessity of infliximab treatment, placebo response, regression to the 
mean or effect of co-medication). One could argue that the effect of infliximab therapy 
may be (partially) determined by peak levels or time integrated AUC rather than by 
minimal inhibitory concentration (MIC), implying that measuring serum trough levels is 
not indicative for clinical effect. This is however not likely as subcutaneous anti-TNF 
agents demonstrate similar efficacy without high peak serum levels [25]. However, this 
issue can only be clarified in an intervention study in which the dose of infliximab is 
tapered down and stopped in patients with anti-infliximab levels and/or suspected 
nontherapeutical infliximab levels. 
15 of the 47 (32%, CI:12-52) patients without an decreased infusioninterval reached the 
outcome measure - DAS28 improvement > 0.6 combined with a DAS ≤ 3.2 - compared to 11 
of the 34 (32%, CI: 9-56) patients with an decreased infusion interval. Decreasing the 
infusion interval reduced the DAS28 score with 0.9 (±1.0) units, which is significantly 
(p=0.01) more compared to the group without a decreased interval (0.2 ±1.2). In the 
patients who received a decreased infusion interval, infliximab serum trough levels 
before interval decrease did not differ between responders and non-responders. 
Follow up cohort: advise to stop infliximab therapy
In 56 visits, it was recommended to stop infliximab therapy as the DAS28 score in these 
patients was > 3.2, during at least two infusion cycles, despite an infusion interval of 4 
weeks. This recommendation to stop infliximab therapy was followed in 13 (23%) of the 
cases (table 3). There was no significant difference in DAS28 scores between patients who 
finally stopped with infliximab compared to patients who continued this therapy. In 7 of 
the 43 patients (16%, CI:3-29%) where infliximab treatment was continued, low disease 
activity was reached after two infusions. Neither infliximab serum trough levels nor anti-
infliximablevels were associated with (non)response after two infusions. 
Follow up cohort: patients with remission and longstanding low disease 
activity
In 12 patients, it was recommended to increase the infusion interval as these patients 
revealed a DAS28 < 2.6 for more than 26 weeks. This advise was followed  in 8 of the 12 
patients (67%). None of these patients flared, both in the patient group with and without 
interval elongation. Of these 8 patients, 4 patients had low infliximab levels (< 1 mg/L) and 
3 patients (of these 4 patients) infliximab antibodies. In the 4 patients who remained on 
the same infusion interval, none of the patients had low infliximablevels.
Finally, 38 patients had longstanding DAS28 scores ≤ 3.2. The treatment did not have to 
be adjusted in these patients at any timepoint. In these patients, 14 (37%: CI: 13-61) patients 
had low infliximab levels (< 1 mg/L), whereas 10 (26%) had detectable anti-infliximab 
antibodies. Higher (> 5 mg/L) infliximab serum trough levels were present in 12 (31.6%) of 
these patients.
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activity is assessed as sufficiently low”. More research is therefore necessary in order to 
assess reasons for non compliance and to develop targeted strategies to optimize 
rheumatologist’s compliance to disease activity guided dosing.
In conclusion, the combination of disease activity guided dosing and therapeutic drug 
monitoring could be a valuable instrument to optimize early detection of non-responders 
to infliximab therapy and also detect patients with acceptable low disease activity despite 
having nontherapeutical infliximab levels. As dose escalation or interval reduction is 
mostly not effective, it’s application should be used with reservations, and patients should 
be switched to other therapy.
In addition to patients with probably non-therapeutical infliximab levels, another 
subgroup of patients with longstanding low disease activity that could benefit from 
therapeutic drug monitoring are patients with supratherapeutical infliximab trough 
levels. In our study 12 (32%) of RA patients with low disease activity had relatively high (> 5 
mg/L) infliximab serum trough levels compared to the suggested mean MIC of 
approximately 1.0 mg/L. A disease activity guided dose decrease study is therefore 
warranted to clarify whether dose reduction to minimal effective serum trough levels 
possible in a substantial number of patients. This dose reduction intervention could 
possibly reduce the risk of dose depended side effects and optimize the cost 
effectiveness.
Although infliximab is a feasible candidate for proof of concept studies in TDM in 
biological treated RA patients, the same approach should be used to optimise therapy 
with other biological therapies (adalimumab, etanercept, abatacept and tocilizumab) in 
RA and other inflammatory diseases. Because of the inter-individual variability of the 
pharmacokinetics and the well defined pharmacokinetic-pharmacodynamic-relationships, 
treatment with biological therapies may be optimized by therapeutic drug monitoring in 
order to increase efficacy, decrease costs and side effects. The latter could be relevant in 
light of the published dose dependant increase in solid and haematological malignancies 
during treatment with monoclonal anti-TNF-alpha antibodies.[28] 
The effect of decreasing dose intervals (increasing dose frequency) on EULAR good 
response compared to no change in therapy was very small to non-existent. This was true 
both in patients with partial response at week 14 and in patients with increased disease 
activity during infliximab every 8 weeks. It should however be noted that the effect of 
dose escalation could be somewhat underestimated, as the disease activity decreased 
somewhat more in patients with a shortened infusion interval compared to patients 
without a decreased interval, and because the rheumatologists seem to be more compliant 
in patients with high than with low disease activity. However, it could also be argued that 
the effect of regression to the mean would also be larger in patients with higher disease 
activity.
The, at best, modest effect of a decreased infusion interval confirms the findings of 
Van Vollenhoven [4], who found equal improvements in effect with dose escalation and 
without dose escalation. In a previous study, we also found that infliximab dosages of 5 
mg/kg can be lowered in nearly all RA patients without increase of disease activity [5]. 
Improvements seen in patients following a period of worsening disease activity, 
irrespective of treatment, seem to be typical of the waxing and waning course of RA and 
many other chronic diseases. Indeed, the only studies that report large positive effects of 
dose escalation are uncontrolled studies. [26,27]
Although the combination of evaluation of disease activity and clinical guidelines 
could provide valuable decision support for optimising the management of RA, we 
observed that despite careful introduction of a disease activity guided protocol in clinical 
practice, the compliance to a disease activity guided protocol is low in this study. This is in 
line with a study by Fransen.[29] where a DMARD change took place, on average, in only 
20% of all cases where the DAS28 exceeded 3.2. The most frequently mentioned reasons 
for not changing DMARDs when DAS28 exceeded 3.2 were “wait and see” and “disease 
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Abstract
Objectives
Development of anti-infliximab antibodies is associated with decreased efficacy and 
increased risk of adverse effects to this agent. Rituximab, a chimeric anti-CD20 antibody, 
could potentially inhibit antibody response to foreign proteins such as infliximab. 
Therefore, we tested whether rituximab can induce seroconversion of anti-infliximab 
antibodies in rheumatoid arthritis (RA) patients previously treated with infliximab.
Methods
RA patients with detectable anti-infliximab antibodies (>12 AU/ml), who were initiated 
on treatment with either rituximab (2 x 1000 mg) or adalimumab (40 mg eow) were 
included in this prospective controlled cohort study. Anti-infliximab antibody levels were 
measured at baseline and after 16 and 24 weeks. The proportion of patients lacking anti-
infliximab antibody levels (<12 AU/ml) at  week 24  and the change in anti-infliximab antibody 
levels were compared between both groups. 
Results
Thirty-two patients were included; 17 were treated with rituximab and 15 with 
adalimumab. In none of the patients, rituximab treatment led to seroconversion of  anti-
infliximab antibodies. After 24 weeks, median serum anti-infliximab levels in the 
rituximab group and adalimumab group decreased from 29 AU/ml to 23 AU/ml and from 
100 AU/ml to 44 AU/ml, respectively. Both univariate and multivariate analyses showed 
that the decrease in anti-infliximab antibody levels was not more pronounced in the 
rituximab group (20% ± 38 reduction) compared to the adalimumab group (36% ± 52 
reduction).
Conclusion
Rituximab treatment neither abrogates anti-infliximab antibodies nor downmodulates 
the change of anti-infliximab antibody levels compared to adalimumab in patients 
previously treated with infliximab.
 Infliximab, a human-murine chimeric monoclonal IgG antibody against tumor necrosis 
factor (TNF) is an effective treatment for rheumatoid arthritis (RA) [1,2]. However, treatment 
is sometimes hampered by the formation of human anti-chimeric antibodies (HACAs) 
against infliximab. Anti-infliximab antibodies have been found in 8% to 43% of RA patients 
treated with infliximab and have been associated with less efficacy and higher adverse 
event rates leading to discontinuation of infliximab [3, 4,5]. Therefore, identification of an 
intervention that can prevent or diminish anti-infliximab antibody formation is warranted 
to improve the long-term effectiveness of this treatment. The best strategy to prevent 
immunogenicity apart from dose loading [2] is concomitant methotrexate treatment, since 
reduced HACA formation occurs in those taking concomitant methotrexate.[1] Strategies 
aimed at reducing HACA levels after their development have not been published thus far. 
Serum antibody levels depend on a balance between the rates of antibody production 
and antibody elimination. In the absence of an active immunological stimulus, experimental 
studies indicate that serum levels are either maintained by long-lived plasma cells in 
protection niches or by short-lived plasma cells continuously generated from memory 
B-cells [6,7,8]. Antibody elimination (half-life time) is determined by the half-life of the 
antibody itself and the presence of the antigen, as formation of immune complexes may 
shorten the half-life time. A strategy aimed at reducing existing HACA levels should therefore 
either inhibit HACA production or increase HACA elimination. 
Rituximab, a human-murine chimeric monoclonal antibody registered for the treatment 
of RA, depletes B cells that have CD20 on their surface. Plasma cells, stem cells and early 
pre-B cells do not express CD-20 and are hence unaffected [6]. The exact effects of B cell 
depletion on primary and secondary antibody responses as well as the maintenance of 
serum antibody titers are as yet unknown.
In small clinical reports, rituximab has been successfully used to treat antibody- 
mediated reactions in allotransplantation [9,10]. Rituximab treatment also resulted in 
decreased serological responses after influenza vaccination, [11,12], but pre-existing antibody 
levels against tetanus and pneumococcal polysaccharide were unaffected by a single course 
of rituximab [7]. With regard to auto-antibodies, rituximab treatment is associated with a 
marked decrease in disease associated auto-antibodies (like rheumatoid factor, auto-
antibodies against factor VIII and anti-neutrophil cytoplasm antibodies) in various 
autoimmune conditions [7,13], although persistently elevated serum autoantibody titers 
have been observed in patients with systemic lupus erythematosus [14]. 
The effect of rituximab on HACAs directed at  infliximab is not known. Since seroconversion 
of HACAs by rituximab treatment could regain the therapeutic efficacy of infliximab, we 
studied the proportion of RA patients with anti-infliximab antibodies in whom treatment 
with rituximab resulted within 24 weeks in the depletion of these antibodies.
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Descriptive statistics were provided using mean (+/- SD) or median (p25-p75) values 
depending on the (non-) parametric distribution of measured variables. The proportions 
of patients with non-detectable anti-infliximab antibody levels after treatment with 
rituximab or adalimumab (primary endpoint) were compared with the Fischer’s Exact 
Test. The anti-infliximab antibody levels at week 0 and at week 24 were compared for each 
group using the Wilcoxon’s rank sum test (non-parametric paired samples). Anti-
infliximab antibody levels of the rituximab and adalimumab group at week 0 were 
compared using the Mann-Whitney U’s test. The percentages of decrease in anti-infliximab 
antibody levels in each group were compared univariately with an independent sample 
t-test, and in a multivariate association model using the percentage of decrease in anti-
infliximab antibody levels as dependent variable, rituximab or adalimumab treatment as 
central determinant, and baseline anti-infliximab antibody level as potential confounder. 
For correlation between non-parametric values a Spearman rank correlation was 
calculated.
Patients and Methods
Patients
Consecutive patients with RA, according to the ACR 1987 revised criteria, who started 
treatment with rituximab between August 2005 and March 2006 in the Sint 
Maartenskliniek (Nijmegen), the University Medical Center Nijmegen and the Academic 
Medical Center (Amsterdam) were prospectively followed. Of the 57 patients included in 
this rituximab cohort, 17 (30%) patients had previously been treated with infliximab and 
had detectable anti-infliximab antibodies (>12 AU/ml). These 17 patients were included in 
the present study. Patients who started adalimumab in the Jan van Breemen Institute in 
the period December 2004 until July 2006 and who had also developed anti-infliximab 
antibodies due to previous infliximab therapy were included as a control group.
There were no exclusion criteria other than the regular contraindications.
Study protocol
Baseline assessment included measurement of disease activity by the Disease Activity 
Score based on evaluation of 28 joints (DAS28) and a standardized intake (demographics, 
disease duration, previous and concomitant medication). Patients received rituximab (2 x 
1000 mg intravenously, day 0 and 15) or adalimumab at a dosage of 40 mg subcutaneously 
every other week. Anti-infliximab antibody measurements before the first administration 
of rituximab and after 16 and 24 weeks (with a maximal window of 2 weeks) were 
compared. 
The primary endpoint was defined as the proportion of patients in whom a single 
course of rituximab eliminated anti-infliximab antibodies (< 12 AU/ml) within 24 weeks. 
The change in anti-infliximab antibody levels between week 0 and week 24 represented 
the secondary outcome. For both endpoints patients treated with adalimumab served as 
control group.
Serum collection was performed during routine care of adult patients. Therefore, this 
study was exempted for reviews by the Research Ethics Committee.
Measurement of serum anti-infliximab antibody levels
Serum anti-infliximab antibody levels were determined by a previously described 
radioimmunoassay [4]. The cut-off level for a positive signal was set at 12 AU/ml (mean +3 
SD of blank serum values). The laboratory staff was blinded for patient characteristics.
Statistical analysis
For the purpose of power analysis, we assumed that the percentage of patients with 
undetectable anti-infliximab antibody levels in the control group after 24 weeks would be 
10%. An attributive seroconversion rate of 50% of the patients was considered clinically 
relevant. With 17 included patients in our study and a 5% significance level using a two-
tailed Fisher’s exact test, this would yield a power of 80% to detect this difference. 
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Figure 1    Anti-infliximab antibody levels (AU/ml) prior to treatment with rituximab or adalimumab (t=0) and 16 
and 24 weeks after treatment
The decrease in anti-infliximab antibody levels was significant in both groups after 24 
weeks (mean decrease: 20% (± 38; p=0.02) and 36% (± 52; p = 0.002)). However, the 
decrease in anti-infliximab antibodies after 24 weeks did not differ significantly between 
the rituximab and adalimumab group (p = 0.2). In patients with high initial anti-infliximab 
antibody levels (higher than the median), antibody levels decreased faster compared to 
patients with low initial anti-infliximab antibody levels (r = 0.75, p < 0.001). Other baseline 
variables were not associated with the change in anti-infliximab antibody levels. A linear 
regression association model showed that baseline anti-inflximab antibody levels did not 
act as a confounder on the relation between decrease in anti-infliximab antibodies and 
received treatment. 
Results
Baseline characteristics of the patients are shown in Table 1. At baseline the median 
anti-infliximab antibody levels (interquartile range (IQR)) were 29 (19-127) AU/ml in the 
rituximab group and 100 (28-416) AU/ml in the adalimumab group, respectively. The anti-
infliximab antibody levels did not differ significantly between the two groups (p = 0.2). A 
negative trend was found between baseline anti-infliximab antibody levels and the 
interval between the last administration of infliximab and start of the present therapy 
(r = -0.32, p = 0.07). No other variables at baseline were associated with anti-infliximab 
antibody levels.
Serum anti-infliximab antibody levels were 26 (13.5-56) AU/ml and 23 (15.5-36) AU/ml 16 
and 24 weeks after rituximab treatment, respectively (Figure 1). Of importance, after 24 
weeks none of the patients treated with rituximab had anti-infliximab antibody levels 
below the cut-off level of 12 AU/ml (primary endpoint). After 16 and 24 weeks of adalimumab 
treatment anti-infliximab antibody levels decreased to 82 (24-102) AU/ml and 44 (16-85) 
AU/ml, respectively. In this group one patient had anti-infliximab antibody levels below 
the cut-off level of 12 AU/ml at week 24.
Table 1    Baseline characteristics of patients
Rituximab group 
(n = 17)
Adalimumab group 
(n=15)
Age (yrs) 56 ± 12 53 ± 12
Woman (n, %) 8 (47) *) 13 (87) *)
Disease duration (yrs) 15.7 ± 9.1 15.8 ± 7.8
Previous Disease Modifying Drugs 
(DMARDs) (n) 
6.5 ± 2.6 *) 3.7 ± 2.1*)
Previous biologicals (n) 2.5 ± 0.9 *) 1.3 ± 0.5 *)
Rheumatoid factor positive (n, %) 17 (100) 13 (87)
Disease activity (DAS28)
at baseline 6.0 ± 1.6 5.0 ± 1.4
Interval  between last infliximab infusion (months) 
and  present therapy (median (p25-p75))
 25 (7.2 - 36)*) 5.8 (2.5-25)*)
Concomitant DMARD at baseline (n, %) 15 (88) 13 ( 87) 
  Methotrexate (n, %) 11 (65) 13 (87)
  Dose (mg/week) 13.6 ± 6.3 16.9 ± 9.4
  Azathioprine (n, %) 2 (12) 0
  Leflunomide (n, %) 1 (6) 0
Oral corticosteroids at baseline (n, %) 10 (59) 5 (33)
  Dose (mg/day) 9.3 ± 2.9*) 4.9 ± 1.9*)
Variables are expressed as mean ± SD unless stated otherwise.
*) P < 0.05
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with rituximab followed by infliximab treatment, or treatment with rituximab during 
infliximab therapy could theoretically lower the production of anti-infliximab antibodies 
and increase the elimination (although the safety of this approach remains to be shown). 
In conclusion, the results of this study indicate that treatment with rituximab after 
discontinuation of infliximab therapy is not effective in depleting pre-existing anti-
infliximab HACAs. 
Discussion
The results presented here show that a single course of rituximab does not lead to non-
detectable levels of anti-infliximab HACAs. Besides, the decrease in anti-infliximab 
antibodies over 24 weeks was not significantly different after rituximab compared to the 
decrease in anti-infliximab antibody levels in the control group of RA patients treated 
with adalimumab after treatment with infliximab.
The internal validity of our study appears to be adequate. The presence of significant 
bias is unlikely, considering the non-selective inclusion and broad inclusion criteria, the 
blinded assessment of anti-infliximab antibody levels and the use of a comparable control 
group. Confounding was considered because initial anti-infliximab antibody levels tended 
to be higher in the adalimumab group compared to the rituximab group, and the initial 
levels of anti-infliximab antibodies were significantly correlated to the decrease in those 
levels at 24 weeks. However, after correction for initial anti-infliximab levels, the decrease 
of anti-infliximab antibody levels still did not  differ between both groups. With regard to 
precision, although the power was limited, the probability of a type II error for a relevant 
difference in the proportion of patients that reach seroconversion is very low due to the 
complete absence of seroconversion in the rituximab group.
There are a few possible explanations for the lack of effect of rituximab on anti-
infliximab HACA levels compared to cases in which rituximab actually affects the levels of 
antibodies, as described above. CD20 positive B cell depletion does not directly interfere 
with total plasma antibody titers, which is confirmed by the fact that pre-existing antibody 
levels against tetanus and pneumococcal polysaccharide were shown to be unaffected 
after a single course of rituximab [7]. Consistent with these data, a recent study on B cell 
depletion in mice demonstrated that, although the majority of peripheral B cells are 
depleted, pre-existing antibody levels do not dramatically decrease after B cell depletion. 
Some long living plasma cells survive independent on repopulation by the B cell 
compartment.[8] 
Although our data show that anti-infliximab antibody levels do not seem to be affected 
by rituximab, this does not necessarily imply that rituximab will not affect the production 
of anti-infliximab antibodies in the presence of infliximab. It is likely that in the absence 
of infliximab anti-infliximab antibodies are produced by long- living plasma cells. 
Conceivably, reintroduction of infliximab in patients with anti-infliximab antibodies 
previously treated with rituximab could lead to decreased formation of anti-infliximab 
antibodies by short-lived plasma cells, since repopulation of CD20 positive cells would be 
needed for optimal antibody production. Moreover, in the presence of a rechallenge with 
infliximab, clearance of anti-infliximab antibodies could increase due to immune complex 
formation. The influence of rituximab on anti-infliximab antibody levels may therefore 
be different in the presence or in the absence of the antigen infliximab. Initial treatment 
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Introduction
The goal of RA treatment is to achieve and maintain the lowest level of disease activity, 
and consequently to prevent the progression of joint destruction and functional 
impairment [1]. This goal can be reached by using the most optimal treatment strategy, 
periodically monitoring patient’s disease activity and side effects, setting goals and by 
rapidly adjusting suboptimal therapy.[2,3] However, clinical trials and clinical practice 
reveal that, despite different new effective treatment options, many patients continue to 
have unacceptable high disease activity[4,5]. Strategies to optimize the pharmacological 
therapy of RA are therefore warranted. 
Two possible strategies to improve treatment outcome were introduced in the general 
introduction (chapter 1): improving adherence and applying therapeutic drug monitoring. 
In this final chapter the role of these two strategies will be further explored by discussing 
five themes that have come up during the studies described in this thesis and that go 
beyond the discussion of the individual studies included in this thesis. These five themes 
are:
Absence of general predictors for non-adherence
Concordance
Assessment of (non-)adherence
Monitoring and differentiation of (non)response
Therapeutic drug monitoring of biologicals: priors, serum trough levels and 
antibodies. 
In addition, recommendations for clinical practice and directions for further research 
will be provided. 
 1 Absence of general predictors for non-adherence
The effectiveness of Disease Modifying AntiRheumatic Drugs (DMARDs) depends not 
only on the innate efficacy of these drugs, but also on patient’s adherence to the intended 
regimen. Similar to other chronic conditions, adherence rates to prescribed medicine 
regimes in RA are mostly low, varying from 58–82% [6-9]. Improving adherence to therapy 
could therefore improve the efficacy of medical treatments. 
Indicators of poor adherence to a medication regimen can be useful to help identify 
patients in need for adherence improving interventions. Furthermore, sometimes, these 
indicators can themselves act as target for a possible intervention. However, although the 
adherence literature reports a variety of sociodemographic and/or clinical variables 
related to adherence, none of these relations was consistently found over different studies 
[7-9]. These findings are also confirmed in Chapter 2.1. In this large study with a random 
selection of 228 RA patients, 32-40% of the patients did not adhere to their DMARD 
prescription. However, similar to the findings published before, none of the possible risk 
factors were strongly related to adherence. These findings suggest that no general 
demographic and/or clinical factors can be used as a possible screening tool for non-
adherent patients. 
Possible explanations for the absence of clear predictors for non-adherence in research 
could be 1) that non-adherence has a stochastic nature, 2) that the most powerful variable 
is not studied yet or 3) that non-adherence is due to various causes in multiple domains. 
Indeed, during individual assessment of non-adherence two types of non-adherent 
behaviour are commonly observed: unintentional (due to forgetfulness or the inability to 
follow the instructions because of poor understanding, regimen complexity or physical 
problems) and intentional (when the patient decides not to take the treatment as 
instructed) [12]. In case of intentional non-adherence, the decision is based on a cost 
benefit analysis of treatment with the costs/risks (concerns) of each treatment weighed 
against the perceived benefits (necessity). [13].
 2 Concordance
It is the patient who decides on a daily basis whether or not to take any medication as 
prescribed [15,16]. Therefore, to enable optimal medication use clinicians have to take 
patient’s opinion into account [16].The patient’s motivation to start and keep using 
medication is influenced by the way in which the patient judges his personal need for the 
treatment relative to his concerns about potential adverse effects. [11] Therefore, clinicians 
should throughout the therapy discuss patient’s perception of the need for the proposed 
treatment and consider individual’s concerns about taking it. This discussion will help to 
foster a patient-physician relationship in which the patient is able to communicate as a 
partner in the selection of treatment and the subsequent review of it’s effect. To achieve 
this shared decision making, clinicians and patients need to be able to discuss concerns 
about treatment regimens. The aim of this discussion is concordance between patient 
and health care provider as to the diagnosis and prognosis of the illness, the treatment 
required and the risks and benefits associated with any such treatment. This point of view 
differentiates adherence (the extent to which the patient’s behaviour matches agreed 
recommendations from the prescriber) from compliance (the extent to which a patient 
follow medical instruction). 
Although shared decision making is an attractive paradigm for improvement of clinical 
communication, observational studies have highlighted that patients are rarely involved 
in the treatment decision process and have a passive role in consultations. [17,18] Physicians 
often fail to communicate important elements of medication use when prescribing new 
medications, which may increase the risk of patient misunderstanding[19]. Research on 
recorded interactions between patients with chronic diseases and their physicians during 
regular visits showed that even when the topic of adherence was raised, it was not always 
discussed [20-22]. This seems to be confirmed in our chapter 2.2., in which we demonstrated 
that supplying the rheumatologist information about patient’s adherence just before 
patient’s visit to the rheumatologist did not change patient’s adherence or patient’s 
beliefs about medication.
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Table 1    Differentiation of (non-)response and subsequent clinical consequences
Disease activity 
after initiation of 
pharmacological treatment
Reason Clinical consequence Consequence of 
strictly disease 
activity guided 
treatment 
Moderate/high disease 
activity
Dose independent 
non-response
Switch to another 
drug
Undertreatment of 
the disease (and 
overtreatment 
with current 
pharmacological 
treatment) when a 
dose-escalation is 
applied
Dose dependent non-
response
Increase dosage Risk for 
undertreatment 
when no dose-
escalation is applied
Low disease activity Response with 
adequate dose
Sustain therapy None
Response with too 
high dose
Decrease dosage Overtreatment
Low disease activity 
due to other factors 
(expectation bias, 
regression to the 
main, placebo-effect, 
co-medication)
Stop therapy Overtreatment
 
The relevance of this distinction could be illustrated with patients with moderate/high 
disease activity despite infliximab treatment: clinicians do not know whether these 
patients have are dosed too low or whether the non-response is dose independent. In 
clinical practice most clinicians decide to increase the infliximab dose. However, a large 
proportion of the patients will not benefit from dose escalation as most studies concluded 
that increasing infliximab dose has limited efficacy. [26-30] These patients will therefore 
be exposed to a longer period of too high disease activity and to the risks associated with 
anti-TNF therapy [31,32]. When a clinician however would decide to switch directly after 
non response without dose increase, the proportion of the patients with a dose dependent 
non-response would be switched unnecessary from infliximab to another drug.
In contrast to the patients with moderate/high disease activity, disease activity guided 
dosing could lead to overtreatment in patients with low disease activity. Current disease 
activity guided dose decrease schedules are often reluctant to lower the dose too fast, in 
order to avoid unnecessary disease flares. As a consequence, periods of more than 6 
 3 Assessment of (non-)adherence
An important methodological challenge for the development and evaluation of new 
interventions to improve adherence is the availability of  a reliable and adequate measure 
of adherence. Several methods for the assessment of adherence are currently available 
including pill counting, refill data, electronic monitoring, and self-report measures or 
even measuring serum levels. However, all these methods can induce bias or random error 
in the measurement of non-adherence and a reliable adherence measurement tool is still 
absent [24]. This tool should have the following requirements: (1) high validity (proving 
ingestion of the medication), (2) reliable and sensitive to change and (3) feasible in daily 
practice 
Furthermore, widely used thresholds defining “good” and “bad” adherence do not exist 
because the dose–response phenomenon is a continuum function. Thus, further research 
is necessary to define and validate adequate outcome measures to reliably assess 
adherence and possible changes in adherences caused by an intervention.
 4 Monitoring and differentiation of response
Another effective instrument to optimize the efficacy of pharmacotherapy in RA is 
disease activity guided treatment. This is confirmed in several studies, which have 
demonstrated that frequent monitoring of disease activity, setting of goals and a quick, 
aggressive escalation protocol can improve the efficacy of RA-treatment considerably 
compared with routine care. [25]
However, disease activity guided treatment strategies are not able to easily, efficiently 
and rapidly distinguish underlying reasons for (not) reaching low disease activity after 
initiation of pharmacological treatment [25]. Patients with moderate or high disease 
activity despite pharmacological treatment, for example, could be divided in two 
subgroups: a subgroup who benefit from a dose escalation from the same drug and a 
subgroup who do not (table 1). In addition, patients with low disease activity after 
treatment initiation could be divided in three subgroups: (1) patients with an adequate 
response on a adequate dose, (2) patients with an adequate response who would also 
have responded on a lower dose and (3) patients with low disease activity which is 
unrelated to the drug but caused by other factors like placebo effect, co-medication and 
regression to the mean. Although it is possible to indentify all subgroups using disease 
activity guided escalation- and de-escalation protocols, for timely, cost-effective  and 
patient friendly decision making an instrument to either identify or to predict to which 
group a patient belongs could improve the efficacy of drug therapy.
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Only an industry consensus with specific recommendations for validation ELISAs to 
support pharmacokinetic assessments of macromolecules is available[35-38].  Following 
the industrial recommendations, the infliximab assay described in this thesis (chapter 3.1) 
has been shown to be rapid, accurate and precise with a quantification range from 0.5-50 
mg/L in human serum. This range covers clinical relevant infliximab concentrations. 
[7, 11]
5.2 Therapeutic drug monitoring of biologicals: serum trough levels
Assessing infliximab serum trough levels in patients with high dose infliximab whose 
infliximab dose was successfully decreased (chapter 3.2), learned that these patients by 
definition had either supra- or nontherapeutical serum trough levels. And although disease 
activity scores could not differentiate between patients with supra-, therapeutical and 
nontherapeutical levels, the treatment strategy should be different between these three 
groups. Whereas treatment of the patient with therapeutical infliximab serum trough 
levels remains unaltered, in case of supratherapeutical infliximablevels the infliximab dose 
could be lowered. This could result in lower costs and possible less adverse effects. In patients 
with low disease activity and nontherapeutical levels, it is important to get insight how long 
the patients are exposed to these nontherapeutical serum trough levels. Especially in 
patients who were exposed to nontherapeutical levels during a substantial period of the 
infusion interval, infliximab does not seem to have added value for these patients as low 
disease activity is not attained by the infliximab treatment.
Thus, although disease activity scores objectify disease activity, a  more direct measure 
of the aetiology of patient improvement is warranted revealing also the cause of the 
effect. Several publications suggested that the assessment of (anti-)infliximab serum 
trough levels may be used to optimize infliximabtreatment [39-42]. However, no 
prospective study so far has assessed the test characteristics of serum infliximab and 
anti-infliximab levels in a cohort of patients being treated based on disease activity to 
determine the value of TDM when added to disease activity guided treatment. In chapter 
3.4 we demonstrate that TDM could be useful in two scenarios: the prediction of 6 months 
response at 6 weeks, and especially in detecting patients with adequate disease activity 
despite having nontherapeutical infliximab levels. TDM was not effective in predicting 
which patients benefit from dose escalation. 
5.3 Therapeutic drug monitoring of biologicals: antibodies.
Treatment with anti-TNF alpha inhibitors, can be associated with antibodies to the 
administered drug. The incidence is reported to be high in infliximab (13-60%), as chimeric 
monoclonocal antibody, compared with the incidence with the fusion-protein etanercept 
(< 5%) or the fully human antibody adalimumab (12%) [39-45]. Immunogenicity can alter 
pharmacokinetics by affecting clearance and biodistribution, it can reduce efficacy, and 
also introduce safety concerns as hypersensitivity and anaphylactic reactions. 
One of the major obstacles in assessing the clinical relevance of immunogenicity is 
however the complexity of measuring antibodies against biological drugs. Assays to 
measure antibodies against biologicals will interfere with the biological as long as the 
months sustained remission are often used, before a dose decrease is started. This 
implicates that in patients who receive infliximab in a too high dose or in patients with 
even infliximab independent low disease activity, dose decrease will be started after a 
relative long period. This overtreatment could lead to more adverse effects and more 
costs.
 
Thus, an adequate instrument to distinguish between the two subcategories of non-
responders and three categories of patients with low disease activity as described above 
is useful as there is pre-test uncertainty to which category the patient belongs. The same 
principle holds true for all biologicals in rheumatoid arthritis. 
 5 Therapeutic drug monitoring of biologicals: priors, serum trough  
  levels and antibodies.
Therapeutic Drug Monitoring (TDM), the measurement and interpretation of drug 
concentration measurements, could potentially be a candidate for identification the two 
subcategories of non-responders and three categories of patients with low disease activity 
in a disease activity guided treatment protocol. This could result in more timely dose 
adjustments, less disease flares caused by  “trial and error” dose adjustments, less adverse 
effects and improved cost effectiveness. Until now, TDM of biological drugs has not been 
used in routine care.
 5. 1 Therapeutic drug monitoring of biologicals: priors
TDM can be used when five requirements are fulfilled[34]:
Table 2    Characteristics of Drugs Applicable for Therapeutic Drug Monitoring [34]
Criteria Chapter
I A drug assay is available 3.1
II There is a large interindividual variability in pharmacokinetic parameters 3.2
III A good relationship exists between plasma drug concentration and therapeutic or 
toxic effect
3.2
IV The therapeutic effect can not be easily and completely assessed by the clinical 
observation;
3.3
V There is a narrow range of concentrations that are (cost-) effective and well tolerated 3.4
A precise, accurate and robust assay for infliximab is essential for tailoring the therapy 
for individual patients. However, despite the increasing number of biological agents, an 
official governmental guideline for the validation of macromolecular therapeutics is 
absent although streamlining of the method validation process is warranted. The U.S. 
Food and Drug Administration (FDA) only describes the bioanalytical method validation 
of small-molecule drugs. This guidance, however, cannot be directly applied to 
macromolecules, due to the heterogeneous nature of macromolecules and the inherent 
variability of immunoassays. 
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Clinical implications
The findings of this thesis has the following clinical implications:
When the therapeutic response to a drug is not as expected, clinicians should consider 
whether the patient is a non-responder or a non-adherent
It is not possible to identify non-adherent patients based on demographic or clinical 
characteristics alone
The presence of pre-infusion anti-infliximab antibodies seem to be a sensitive and 
specific predictor for low/no-infliximab serum trough levels halfway trough the 
infusion cycle.
Lowering the dose of infliximab combined with monitoring the disease activity should 
be considered in every RA-patient receiving higher doses (> 3 mg/kg/4-8 weeks) 
infliximab.
Dose escalation or interval decrease during infliximab therapy in RA should be  used 
with reservations, as dose escalation or interval reduction is mostly not effective.
The measurement of infliximab serum trough levels after 6 weeks combined with the 
actual DAS28-score seems to have some added value above disease activity guided 
dosing alone to recognize non-responders to infliximab therapy. However validation in 
a separate cohort is warranted.
Serum anti-infliximab levels should be measured in patients with longstanding low 
disease activity (> 6 months) to detect patients with possible nontherapeutical or 
supratherapeutical infliximab levels
Rituximab could not be used as a therapy to abrogate existing anti-infliximab 
antibodies
Future research
Research on individualizing and optimizing treatment response in patient with RA is a 
promising area of research. Based on this thesis the following recommen dations for future 
research could be done:
Research is needed on the efficacy of interventions that are tailored to individual 
primary reason(s) for non-adherence
Adequate outcome measures to reliably assess adherence and possible changes in 
adherences should be defined and validated
Proper specific recommendations for validation of macromolecules should be defined 
and used in industrial, governmental and scientific settings
More research is necessary to assess physician’s reasons for non compliance to guidelines 
in order to improve guideline performance
The predictive value of TDM for low disease activity after dose reduction or treatment 
discontinuation should be studied in RA patients on biologicals with longstanding low 
disease activity. 
Research should be done to explore the possibilities of therapeutic drug monitoring in 
other biopharmaceuticals in rheumatology (adalimumab, etanercept, tocilizumab, 
abatacept), in other disciplines (gastro-enterology, dermatology, oncology) and in 
biosimilars
these agents are present in the serum. If the production of antibodies exceeds the amount 
of the drug in the serum, all drug applied is cleared from the circulation and only free 
antibody to the drug can be measured. This leads to underestimation of  the incidence of 
Human AntiChimeric Antibodies (HACA)- formation and overall HACA production [46]. 
Currently, it is uncertain whether the measurement of anti-infliximab antibodies has a 
additional value next to measuring infliximab trough levels. However, measurement of 
anti-infliximab antibodies at the end of an infusion interval can be used as good proxy for 
low infliximab-levels throughout most of the infusion cycle. (chapter  3.3), as the presence 
of anti-infliximab levels is associated with no/low levels of infliximab in 71% of patients 
halfway trough the infusion. Most patients with anti-infliximab antibodies at the end of 
an infusion cycle have therefore nontherapeutical infliximablevels most of the time. This 
implies that patients with both low disease activity and anti-infliximab antibodies at the 
end of the infusion interval do not seem to benefit from infliximab at all.
Another theoretical application of the determination of HACA formation could occur 
when interventions should exist that reduce the anti-body formation. However, the results 
in chapter 4 study suggest that treatment with rituximab in persons with existing anti-
infliximab antibodies, does not affect serum trough levels of anti-infliximab antibodies.
5.4 Applicability of therapeutic drug monitoring of other anti-TNF agents and other 
biological drugs
Biologicals represent one of the fastest growing segments of the pharmaceutical 
industry with an annually grow of 12-15% [47]. Because of the inter-individual variability 
of the pharmacokinetics of biologicals and the well defined pharmacokinetic-
pharmacodynamic-relationships, treatment with biologicals may be optimized by 
therapeutic drug monitoring. Monitoring serum levels and levels of neutralizing 
antibodies during biological therapy may help to optimize dose regimens for individual 
patients, diminish the risk of serious adverse effects, and prevent continued and probably 
futile use of these drugs in patients with detectable neutralizing antibodies.
However, more research should be done to relate serum levels of biological therapies to 
clinical response or to adverse effects. Currently, besides infliximab, only (anti)adalimumab 
serum trough concentration have shown to be related to clinical effect [48]. For etanercept, 
sufficient studies for establishing adequate relationships between etanercept serum 
levels and clinical effect are lacking [49]. Anti-etanercept antibodies were however not 
related to (lack of) effect in patients with spondylarthropathy [50]. 
For non-rheumatologic indications, data on the use of pharmacokinetic parameters 
with biological therapy are even more scarce. However, an example of a possible candidate 
for TDM is the biological alemtuzemab, a humanised monoclonal antibody directed 
against the CD52 antigen which is approved for the treatment of B-cell chronic lymphocytic 
leukemia (CLL). Higher serum alemtuzumab levels were in a small group of patients 
associated with better treatment responses [51]. Future studies are however needed to 
improve the pharmacokinetic (PK) model of alemtuzumab and to explore a PK-guided 
dosing schedule, with the goal of maximising the therapeutic benefit of this agent.
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Chapter 1
General introduction
Rheumatoid arthritis is a chronic, progressive, painful and potentially debilitating 
autoimmune disease with a lifetime cumulative incidence of approximately 1%. The 
disease is characterized by chronic inflammation of the synovium, which over time may 
result in damage to the joints and loss of physical function. The treatment of RA, which 
usually entails a combination of drug therapy and other non-drug therapies, aims to 
achieve and maintain the lowest level of disease activity, and consequently prevent the 
progression of joint destruction and functional impairment. Current treatment guidelines 
therefore emphasize the use of disease-modifying antirheumatic drugs (DMARDs) early 
in the disease, as early aggressive management of RA with DMARDs provides better 
outcomes in regards to radiological outcomes, quality of life and physical function. Besides 
early treatment, close monitoring of individual disease activity and adapting the 
treatment is a second available step to improve the efficacy of RA-therapy. Finally, new 
therapies, including biologic agents, the use of combination DMARD therapy and the 
resurgence of low-dose corticosteroid therapy have finally also improved therapeutic 
outcomes. 
However, clinical trials and research in clinical practice reveal that, despite different 
new effective treatment options, many patients continue to have unacceptable high 
disease activity. Strategies to optimize the available pharmacological therapeutic options 
in RA are therefore warranted. Two possible strategies to improve treatment outcome in 
RA were studied in this thesis: improving adherence to DMARD-therapy and therapeutic 
drug monitoring of one of the biological agents: infliximab.
Chapter 2
Adherence  in RA
The effectiveness of RA-therapy may be limited by inadequate patient adherence to 
medication and by discrepancies between the physician-prescribed regimen and the 
regimen actually used by the patient. As with other chronic conditions, adherence rates to 
prescribed medicine regimes in RA patients are low, varying from 30–80%. Failure to take 
medication has important consequences. It not only reduces efficacy of the treatment, 
but wastes also healthcare resources. An effective intervention to support RA-patients to 
adhere to their medication could make a major contribution to adequate 
pharmacotherapy. 
Chapter 2.1
Knowledge of factors associated with medication adherence in RA could help physicians 
to identify patients who would benefit from adherence improving interventions. Insight 
in these associates could also facilitate to tailor adherence-interventions to individual’s 
primary reasons for non-adherence. Few studies, however, have examined the prevalence 
and risk factors for adherence to DMARDs in patients with RA. In chapter 2.1 we therefore 
studied adherence rates in a large random population (228 patients) of patients with RA, 
and tried to identify potential risk factors for non-adherence. Adherence was measured 
using two questionnaires: the Compliance Questionnaire on Rheumatology (CQR) and the 
Medication Adherence Report Scale (MARS). The CQR is the only validated rheumatology-
specific adherence questionnaire. Depending on the instrument used, 68% (CQR) and 
60% (MARS) of the patients were adherent to DMARDs. Non-adherence was not associated 
with demographic and clinical characteristics, satisfaction about information, medication 
concerns and coping styles. Disease duration, the number of perceived side-effects and 
beliefs about the necessity of the medicine were weakly associated with adherence. As 
none of the possible risk factors were strongly related to adherence, no general risk factor 
in this study seems to be powerful enough as a possible screening tool or target for 
adherence-improving interventions. 
Chapter 2.2
The effectiveness of adherence improving interventions could possibly be improved by 
selectively targeting these interventions to non-adherent patients. However, a consistent 
finding in the adherence literature is that physicians are unable to identify non-adherent 
patients correctly. Therefore, we developed a pharmacotherapeutic consult to provide the 
rheumatologist structured information about drugs used, side effects, and non-adherence 
risk measured by the CQR. The outcome of this assessment was reported to the 
rheumatologist in writing. The effectiveness of this information on medication use, 
adherence and medication beliefs was studied in chapter 2.2. However, this study showed 
that supplying the rheumatologist a report with information about medication use and 
adherence did not change patient’s adherence to medication. Beliefs about medication, 
patient’s satisfaction about information on medication and physical functioning were 
also not significantly altered. Further research is therefore needed to develop and evaluate 
interventions to optimize medication management.
Chapter 3
Therapy guiding by therapeutic drug monitoring of infliximab
Therapeutic drug monitoring of serumlevels of anti-TNF-alpha biopharma ceuticals 
could be a strategy to improve efficacy of these drugs. Anti-TNF have large inter- and intra-
individual variability in pharmacokinetics and long elimination half-lives. Data derived 
from both rheumatology and gastro-enterology patients suggest that serum trough 
concentrations of (anti) infliximab, (anti)adalimumab and etanercept may be used to 
optimize dose regimens and prevent prolonged use of ineffective therapy. 
Chapter 3.1
A prerequisite for applying therapeutic drug monitoring is the availability of a validated 
accurate and precise analytical method for the quantitative evaluation of infliximab. For 
this purpose, chapter 3.1 describes the validation of a quantitative enzyme linked 
immunosorbent assay (ELISA) for the quantification of infliximab in human serum. The 
analytical performance of this infliximab ELISA indicated that this assay can be used for 
monitoring concentration levels of infliximab in human serum in order to help to optimize 
the dosing and scheduling of infliximab therapy. 
4 3.5 3.4 3.3 3.2 5 5 2.2 2.1 2 1
146
Summary 43.53.43.33.2552.22.121
147
Summary
Chapter 3.4
Several publications suggested that the assessment of (anti-)infliximab serum trough 
levels may be used to optimize infliximabtreatment. However, as yet no prospective study 
has assessed the test characteristics of serum infliximab and anti-infliximab levels in a 
cohort of patients being treated based on disease activity, in order to determine the value 
of TDM when added to disease activity guided treatment. In chapter 3.4 we demonstrate 
that TDM could be useful in two scenarios: the prediction of 6 months response at 6 
weeks, and the detection of the significant number of patients with adequate disease 
activity despite having nontherapeutical infliximab levels. TDM was not effective in 
predicting which patients benefit from dose escalation.
Chapter 3.5
The presence of non-therapeutical infliximab levels, found in previous studies, could 
partially be explained by the formation of human antichimeric antibodies against 
infliximab (HACAs) which occurs in 8% to 43% of the RA patients. The formation of 
antibodies against infliximab has been associated with altered infliximab pharmacokinetics 
and reduced serum infliximab concentrations over time in patients with RA. Therefore, an 
intervention that can prevent or diminish anti-infliximab antibody formation could 
possibly improve the long-term effectiveness of this treatment. Rituximab, a chimeric 
monoclonal antibody that selectively depletes CD20-positive B lymphocytes, could 
potentially inhibit the human antibody response against infliximab. Therefore, we 
describe in chapter 3.5 a prospective study with 32 patients which tested whether 
treatment with rituximab could be an effective intervention to diminish anti-infliximab 
antibody formation in patients with RA formerly treated with infliximab. However, 
rituximab treatment neither abrogates anti-infliximab antibodies nor down modulates 
anti-infliximab antibody levels compared to adalimumab in patients previously treated 
with infliximab. Rituximab can therefore  not be used as a therapy to abrogate existing 
anti-infliximab antibodies in patients not currently receiving infliximab. 
Chapter 4
General discussion
In the general discussion the main findings are discussed and final thoughts on future 
research are given. This aim of this thesis was to further increase knowledge of two 
strategies that could help to improve the efficacy of DMARD/biological therapy in RA: 
improving adherence to DMARD-therapy and the added value of therapeutic drug 
monitoring of (anti)infliximab serum trough levels in patients with RA
As non-adherence is a major problem that affects approximately one third of RA-
patients who use DMARDs, clinicians should consider the adherence in patients with 
insufficient drug response. However, non-adherent patients are not easily to identify, as 
no demographic- or clinical risk factor seem to be powerful enough as a possible screening 
tool or target for adherence-improving interventions. This implicates that non-adherence 
barriers should be assessed on an individual basis. Future research is necessary to 
determine the efficacy of interventions that are tailored to individual primary reason(s) 
for non-adherence.
Chapter 3.2
Although only a small subset of patients with RA benefits from higher than standard 
dose of infliximab (> 3 mg/kg/8 wks), dose escalation of infliximab is frequently applied in 
clinical practice. A possible solution for avoiding individual overdosing of antiTNF-alpha 
could be titration of the infliximab dose based on actual disease activity scores. Possible 
benefits of this approach include a substantial reduction in costs and possible reduction 
in dose dependent side effects. In addition to dose titration based on disease activity, 
determination of serum trough concentrations of infliximab and anti-infliximab 
antibodies may also help to optimize treatment. Knowledge of the (anti-) infliximab 
serum-concentrations could after all provide auxiliary information for the decision 
whether a dose escalation or de-escalation is necessary. In chapter 3.2 we confirmed in a 
study including 18 patients that high infliximab dosages (5 mg/kg) indeed could be 
lowered in the majority of RA patients (16 patients) using DAS28 guided dose titration 
without an increase of disease activity. Lowering the dose of infliximab should therefore 
be considered in every patient receiving higher doses infliximab. Assessing infliximab 
serum trough levels in patients with high dose infliximab whose infliximab dose was 
successfully decreased, showed us that these patients had either supra- or nontherapeutical 
serum trough levels. 
Chapter 3.3
Although disease activity scores can not differentiate between patients with low 
disease activity and supratherapeutical, therapeutical or nontherapeutical levels of 
infliximab, the treatment strategy should be different between these three groups. 
Whereas treatment of the patient with therapeutical infliximab serum trough levels 
remains unaltered, in case of supratherapeutical infliximablevels the infliximab dose 
could be lowered. This could result in possible less adverse effects and lower costs. In 
patients with low disease activity and nontherapeutical levels, it is important to get 
insight how long the patients are exposed to these nontherapeutical serum trough levels. 
Especially in patients who were exposed to nontherapeutical levels during a substantial 
period of the infusion interval, infliximab does not seem to have added value for these 
patients as low disease activity is not attained by the infliximab treatment. Therefore, 
more insight is necessary in the course of (anti)infliximab levels between an infusion cycle 
of two infusions in patients with RA. This knowledge is needed in order to assess at what 
moment patients develop low/no infliximab trough levels and/or detectable anti-
infliximablevels. In chapter 3.3 we describe that most anti-infliximab forming patients 
have detectable anti-infliximab antibodies halfway through an infusioncycle. This implies 
that these patients are exposed to nontherapeutical infliximablevels during more than 
halve of their infusion cycle. As none of the patients without anti-infliximab antibodies 
had no/low-infliximab levels halfway through the infusioncycle, the presence of pre-
infusion anti-infliximab antibodies seems a sensitive and specific predictor for no/low 
infliximab-levels halve of the infusion cycle. 
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Monitoring serum levels and levels of neutralizing antibodies during biological therapy 
may help to optimize dose regimens for individual patients, diminish the risk of serious 
adverse effects, and prevent continued and probably futile use of these drugs in patients 
with non-therapeutic drug levels. The predictive value of TDM for low disease activity, 
after dose reduction or treatment discontinuation, should however be studied in RA 
patients on biologicals with longstanding low disease activity. 
Research should also be done to explore the possibilities of therapeutic drug monitoring 
in other biopharmaceuticals in rheumatology (adalimumab, etaner cept, tocilizumab, 
abatacept), in other disciplines (gastro-enterology, derma tology, oncology) and in 
biosimilars
Further research into individualized interventions, like improving adherence or TDM-
guided drug therapy, could help to optimize pharmacotherapy in patients with rheumatoid 
arthritis. A multidisciplinary approach is therefore recommended in which rheumatologists, 
pharmacists, psychologists and/or laboratory technicians integrate their knowledge in 
order to develop efficacious interventions to optimize  pharmacotherapy in patients with 
RA.
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Hoofdstuk 1
Algemene inleiding
Reumatoïde Artritis (RA) is een chronische aandoening waarbij verschillende 
gewrichten, waaronder meestal die van de handen en voeten, aangedaan zijn. De 
gewrichten zijn hierbij pijnlijk, gezwollen en stijf. Behalve gewrichten kan RA ook andere 
organen aandoen, zoals het weefsel rondom een gewricht, de huid, ogen en longen. Veel 
patiënten met RA hebben daarom niet alleen last van gewrichtsklachten, maar ook van 
algemene verschijnselen zoals moeheid, malaise, vermagering en temperatuursverhoging. 
Reumatoïde artritis komt ongeveer voor bij 0,3-1,5% van de Nederlanders. RA komt twee- 
tot driemaal zo vaak voor bij vrouwen als bij mannen en kan op iedere leeftijd ontstaan, 
maar het meest frequent tussen 40 en 60 jaar. Zonder behandeling leidt RA tot een steeds 
verdere beschadiging van de gewrichten, waardoor deformaties ontstaan en het 
functioneren kan afnemen. 
De huidige behandeling van RA heeft drie doelen: onderdrukken van de klachten zoals 
pijn en ontsteking, voorkomen van gewrichtsschade en beperken van functieverlies. 
Naast medicamenteuze therapie kan de behandeling van RA bestaan uit oefentherapie, 
het aanleren van leefregels en manieren van omgaan met de ziekte. Daarnaast worden 
ook psychotherapie en chirurgische interventies toegepast. De medicamenteuze 
behandeling van RA bestaat enerzijds uit middelen die symptomen (pijn, stijfheid en 
zwellingen) verlichten. Anderzijds probeert men met de antireumatische therapie (Disease 
Modifying AntiRheumatic Drugs (DMARDs)), waartoe ook corticosteroïden en biologicals 
behoren, het destructieve beloop van de aandoening op zowel de korte als de lange 
termijn af te remmen. DMARDs kunnen namelijk een gunstig effect op de ziekteactiviteit 
hebben, de radiologische schade beperken en het verlies aan functioneren voorkomen. 
Van sulfasalazine, methotrexaat, leflunomide, ciclosporine, adalimumab, anakinra, 
etanercept, infliximab, abatacept en rituximab is in dubbelblinde gecontroleerde 
onderzoeken vastgesteld dat de progressie van röntgenologisch waarneembare 
gewrichtsschade geremd wordt.
In de afgelopen jaren heeft de behandeling van patiënten met RA een aantal belangrijke 
veranderingen ondergaan. Allereerst is de focus verschoven van symptoombestrijding 
naar onderdrukking van ziekteactiviteit, met als gevolg dat er minder schade aan het 
bewegingsapparaat ontstaat, en dat het lichamelijk functioneren intact blijft. Daartoe 
wordt tegenwoordig zo vroeg mogelijk gestart met DMARDs. Immers, wanneer mensen 
met RA reeds in een vroege fase van de aandoening worden behandeld met antireumatica, 
treedt uiteindelijk minder gewrichtsschade op. Daarnaast zijn er in de afgelopen jaren 
nieuwe antireumatica op de markt gekomen die zich van de traditionele antireumatica 
onderscheiden doordat ze veel sneller effect hebben op het ziekteproces. Deze middelen, 
de biologicals, zijn ontwikkeld op basis van biotechnologie en remmen specifiek bepaalde 
ontstekingseiwitten en ontstekingscellen in het bloed. Zo blokkeert infliximab, een van de 
biologicals, de werking van het ontstekingseiwit tumor necrosis factor alfa (TNF-alfa). 
Andere TNF-alfa remmers zijn adalimumab en etanercept. Deze middelen hebben over 
het algemeen een gunstige balans tussen  effectiviteit en bijwerkingen profiel maar zijn 
erg duur (gemiddeld 15.000 euro per jaar). Ten slotte is de afgelopen jaren duidelijk 
geworden dat in de zorg voor patiënten met RA veel gezondheidswinst valt te boeken 
door de patiënten met behulp van monitoring nauwkeurig te volgen en de medicatie aan 
te passen aan de ziekteactiviteit. 
Ondanks de sterk verbeterde medicamenteuze behandelopties en –strategieën blijkt 
uit klinische trials en uit de klinische praktijk, dat te veel patiënten nog steeds een te hoge 
ziekteactiviteit hebben. Enerzijds worden daarom nieuwe geneesmiddelen ontwikkeld, 
anderzijds is het ook wenselijk dat gekeken wordt op welke wijze behandeling met de 
huidige middelen verder geoptimaliseerd kan worden. Twee mogelijke strategieën om de 
doeltreffendheid en doelmatigheid van de farmacotherapie bij RA te verbeteren zijn 
onderzocht in dit proefschrift (1) het verbeteren van de therapietrouw op DMARDs en (2) 
de mogelijke meerwaarde van de introductie van therapeutic drug monitoring (het 
meten van de hoeveelheid geneesmiddel in het bloed, en op basis daarvan de dosis 
evalueren) bij biologicals, en dan in het bijzonder infliximab.
Hoofdstuk 2
Therapietrouw bij RA
DMARDs zijn belangrijke geneesmiddelen bij de behandeling van reumatoïde artritis 
die zorgen dat de klachten afnemen en ook de gewrichtsbeschadiging stopt. Een 
belangrijke randvoorwaarde voor therapeutisch succes is echter wel dat de patiënt de 
geneesmiddelen volgens voorschrift gebruikt. Wie de juiste dosis op het juiste tijdstip 
gebruikt, wordt therapietrouw genoemd. Uit relatief kleine onderzoeken blijkt echter dat 
ongeveer 58-82% van alle patiënten met RA, zijn/haar geneesmiddelen regelmatig 
overslaat. Hierdoor kan het effect van deze middelen afnemen, neemt de kans op 
bijwerkingen toe en wordt er niet doelmatig met de geneesmiddelen omgegaan. 
Gebrekkige therapietrouw is een universeel probleem bij chronische aandoeningen: men 
schat dat ongeveer de helft van alle patiënten met een chronische aandoening niet 
therapietrouw is.
Hoofdstuk 2.1
Het lijkt dus belangrijk om mensen die niet therapietrouw zijn op te sporen, om 
vervolgens bij deze mensen de reden van therapieontrouw te achterhalen en hier een 
interventie op te doen. Echter, hoe herken je therapieontrouwe patiënten? Tot op heden 
zijn er slechts enkele, kleine studies gedaan naar therapietrouw bij mensen met RA die 
DMARDs gebruikten. In hoofdstuk 2.1 beschrijven we daarom een onderzoek in een grotere 
populatie RA-patiënten (228 patiënten) die DMARDS gebruiken. In deze onderzoekspopulatie 
is de therapietrouw gemeten en tevens gekeken welke factoren als potentiële indicator 
voor therapieontrouw zouden kunnen worden gebruikt. Therapietrouw werd gemeten 
met behulp van twee meetinstrumenten: de CQR (Compliance Questionnaire on 
Rheumatology en de MARS (Medication Adherence Report Scale).  De CQR is op dit moment 
de enige vragenlijst voor het vaststellen van therapietrouw die binnen de reumatologie 
gevalideerd is. Op basis van de CQR bleek 68% van de RA patiënten therapietrouw te zijn, 
volgens de MARS was het percentage therapietrouwe patiënten 60%. Therapieontrouw 
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van de patiënten die infliximab gebruiken anti-stoffen tegen dit middel. Door de anti-
infliximabvorming scheidt het lichaam infliximab sneller uit, waardoor de hoeveelheid 
infliximab in het bloed daalt of zelfs afwezig is. Uiteindelijk zal hierdoor het geneesmiddel 
minder effectief zijn.
Hoofdstuk 3.1
Een belangrijke randvoorwaarde voordat TDM toegepast kan worden is de 
beschikbaarheid van een gevalideerde accurate en precieze analytische kwantitatieve 
bepalingsmethode voor infliximab. In hoofdstuk 3.1 wordt de validatie beschreven van de 
ELISA (enzyme linked immunosorbent assay) voor de kwantitatieve bepaling van infliximab 
in serum. Na de validatieprocedure bleek de beschikbare ELISA accuraat en precies te zijn, 
waardoor deze toegepast kan worden bij de TDM van infliximab. 
Hoofdstuk 3.2
Ondanks het feit dat slechts een beperkte groep patiënten met RA baat heeft bij een 
hogere dosis infliximab dan de standaarddosis (3 mg/kg/8 weken), wordt de dosis 
infliximab in de dagelijkse praktijk regelmatig verhoogd. Hierdoor lijkt een substantieel 
aantal patiënten onnodig een te hoge dosis te ontvangen, waardoor de kans op 
dosisafhankelijke bijwerkingen toeneemt en tevens onterecht hoge kosten worden 
gemaakt. Een van de mogelijke instrumenten om zinnig en zuinig met deze 
dosisverhogingen om te gaan, en zo onnodige dosisverhogingen te voorkomen, zijn 
dosisaanpassingen op basis van de ziekte-activiteit. Immers, door ziekte-
activiteitsbepalingen kan het effect van een dosisverhoging worden geobjectiveerd. 
Naast ziekte-activiteitsbepalingen, zouden infliximab en anti-infliximab serum 
concentraties mogelijk ook gebruikt kunnen worden om te kijken of een dosisverhoging 
of –verlaging zinvol is.
In hoofdstuk 3.2 bevestigen we bij 18 RA-patiënten met hoge dosis infliximab (5 mg/
kg), dat de dosis infliximab in de meerderheid van de patiënten (16 patiënten) daadwerkelijk 
verlaagd kan worden zonder toename van de ziekte-activiteit. Het is dan ook raadzaam 
om bij elke patiënt die een hoge dosis infliximab krijgt, regelmatig te proberen om de 
infliximab dosis af te bouwen. Opvallend was verder dat de meeste patiënten (10 van de 
16) waarbij de dosis infliximab kon worden verlaagd hetzij hele lage- danwel hele hoge 
infliximabspiegels in het bloed hadden. Patiënten met hoge infliximabspiegels lijken 
supra-therapeutische (hoger dan therapeutisch noodzakelijke) spiegels te hebben, en bij 
deze patiënten kan bekeken worden of de dosering afgebouwd kan worden. Patiënten 
met zeer lage infliximabspiegels lijken hun lage ziekte-activiteit niet te danken te hebben 
aan deze zeer waarschijnlijk niet effectieve infliximab behandeling. Deze patiënten lijken 
eerder ondanks de infliximab een lage ziekte-activiteit te hebben. Bij deze patiënten dient 
de zin van infliximab behandeling opnieuw te worden overwogen. 
Hoofdstuk 3.3
Wanneer de ziekte-activiteit bij een patiënt die wordt behandeld met infliximab wordt 
gemeten, zegt dat niets of een patiënt therapeutisch te hoge-, normale of te lage- 
infliximabspiegels heeft. Toch is het handig om dit te weten omdat elk van bovenstaande 
bleek niet geassocieerd te zijn met demografische- of klinische variabelen, tevredenheid 
over de voorlichting over medicatie, zorgen over geneesmiddelgebruik en diverse coping 
stijlen. Ziekteduur, het aantal bijwerkingen en de mate waarin men de noodzaak van de 
medicatie inzag bleken geassocieerd te zijn met therapietrouw. Echter, geen van deze 
associaties was sterk, waardoor er op basis van dit onderzoek geen risicofactor aangewezen 
kon worden waarmee therapieontrouwe patiënten herkend konden worden. Deze 
bevindingen zijn in lijn met andere onderzoeken bij chronische aandoeningen, ook bij 
deze onderzoeken kon geen duidelijke voorspellende factor gevonden worden waarmee 
therapieontrouwe mensen makkelijk geïdentificeerd kunnen worden. 
Hoofdstuk 2.2
Er zijn aanwijzingen dat therapietrouwbevorderende interventies effectiever zijn, 
wanneer deze interventies alleen worden toegepast bij therapieontrouwe patiënten. 
Echter, uit verschillende studies blijkt dat artsen nauwelijks therapieontrouwe patiënten 
kunnen herkennen. Binnen de Sint Maartenskliniek is daarom een interventie ontwikkeld 
(het Farmacotherapeutisch PréConsult). Dankzij dit consult krijgt de reumatoloog vlak 
voor het spreekuur een actueel geneesmiddeloverzicht van de patiënt uitgereikt. Op dit 
geneesmiddelenoverzicht staat tevens vermeld welke score de patiënt op de CQR gehaald 
heeft en of de patiënt derhalve waarschijnlijk therapietrouw of –ontrouw is. Het onderzoek 
dat de effectiviteit van deze interventie beschrijft staat weergegeven in hoofdstuk 2.2. Uit 
dit onderzoek blijkt dat het verstrekken van een actueel overzicht van de therapietrouw 
van de patiënt aan de arts, geen invloed heeft op de therapietrouw van de patiënt. De 
cognities over de noodzaak en de zorgen over het geneesmiddelgebruik, de tevredenheid 
over de voorlichting en het functioneren van de patiënt werden ook niet beïnvloed door 
deze interventie. Nieuw onderzoek is daarom noodzakelijk om een nieuwe interventie te 
ontwikkelen die de therapietrouw verbetert . 
Hoofdstuk 3
De meerwaarde van infliximab-bloedspiegelbepaling bij het bege lei den 
van mensen die infliximab toegediend krijgen
Therapeutic Drug Monitoring (TDM) is het analyseren van geneesmiddelen in bloed of 
andere lichaamsvloeistoffen met het doel het effect van de therapie met geneesmiddelen 
te verbeteren. Eerder onderzoek heeft laten zien dat het klinisch effect van infliximab, 
adalimumab en etanercept in het bloed, gerelateerd is aan de dalspiegel (hoeveelheid 
geneesmiddel in het bloed vlak voor het nieuwe infuus) van deze middelen. De klinische 
toepassing van deze relatie tussen het effect en de bloedspiegels (feitelijk het toepassen 
van TDM), is echter nog onvoldoende uitgekristalliseerd. In hoofdstuk 3 van dit proefschrift 
worden daarom vijf onderzoeken beschreven die ons meer inzicht geven of TDM ook 
meerwaarde kan hebben om de therapie met infliximab te optimaliseren. Wanneer TDM 
bij infliximab succesvol blijkt kan de opgedane kennis verder worden toegepast bij de 
andere biologicals zoals de anti-TNF middelen etanercept en adalimumab. Al deze 
middelen lijken geschikt voor TDM, omdat er grote verschillen zijn in de snelheid waarmee 
deze middelen worden uitgescheiden door het lichaam. Dit kan onder andere worden 
verklaard door de vorming van antistoffen tegen het biological. Zo ontstaan er bij 8-43% 
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Rituximab is een geneesmiddel dat bepaalde witte bloedcellen (de B lymfocyten) 
tijdelijk uitschakelt. Deze B-lymfocyten maken deel uit van het afweersysteem dat 
verantwoordelijk is voor de vorming van anti-stoffen. Op theoretische gronden zou 
rituximab derhalve de antistofvorming tegen infliximab kunnen remmen. Dit is 
onderzocht in hoofdstuk 3.5, waarbij in een prospectieve studie onder 32 patiënten met 
RA gekeken is of rituximab daadwerkelijk de hoeveelheid anti-infliximab antistoffen in 
het bloed kan verminderen. Hierbij werden de anti-infliximabspiegels van mensen 
gemeten nadat men gestopt was met infliximab, om vervolgens hetzij met rituximab 
danwel met adalimumab (controle) behandeld te worden. Rituximab bleek er echter niet 
voor te kunnen zorgen dat de anti-infliximab antilichamen eerder uit het bloed verdwenen 
dan bij de controlegroep die werd behandeld met adalimumab. 
Hoofdstuk 4
Algemene discussie
In hoofdstuk 4, de algemene discussie, worden de onderzoeken en de resultaten van dit 
proefschrift in een breder context geplaatst. Met dit onderzoek is meer kennis verkregen 
over twee mogelijke strategieën om de doeltreffendheid en doelmatigheid van de 
farmacotherapie bij RA te verbeteren nader te onderzoeken. Enerzijds het verbeteren van 
de therapietrouw op DMARDs en anderzijds de mogelijke meerwaarde van de introductie 
van therapeutic drug monitoring
Ook uit dit proefschrift blijkt dat therapieontrouw vaak voorkomt: bij ongeveer 
eenderde van alle patiënten met RA. Mocht een patiënt derhalve niet reageren op zijn of 
haar geneesmiddel, dan dient een behandelaar zich altijd af te vragen of de patiënt 
daadwerkelijk niet reageert op het geneesmiddel of dat de therapietrouw onvoldoende 
was. Patiënten die therapieontrouw zijn, kunnen echter niet makkelijk aan bepaalde 
demografische of klinische parameters herkend worden. Dit betekent dat voor iedere 
individuele patiënt de therapietrouw opnieuw in kaart gebracht moet worden. Ook zal 
per persoon gekeken moeten worden wat mogelijke barrières zijn bij het gebruik van 
geneesmiddelen. Verder onderzoek is vervolgens nodig om te kijken of therapietrouw 
verbeterende interventies gericht op individuele barrières bij het geneesmiddelgebruik 
effectief zijn om therapie-ontrouw te behandelen.
Therapeutic Drug Monitoring van (anti-)infliximab spiegels in serum lijkt zinvol om de 
respons op dit middel al vroegtijdig te voorspellen en om mogelijk onnodig gebruik van 
infliximab bij patiënten met lage ziekte-activiteit en non-therapeutische spiegels tegen 
te gaan. Hierdoor kunnen dosis-afhankelijke bijwerkingen mogelijk verminderd worden 
en kosten bespaard worden. 
In welke mate TDM meerwaarde heeft boven ziekte-activiteit gestuurd afbouwen, 
moet blijken uit vervolgstudies. In deze onderzoeken zal gekeken worden in welke mate 
TDM toegepast kan worden om patiënten te selecteren, die in aanmerking komen om 
infliximab af te bouwen/te stoppen. Daarnaast is verder onderzoek noodzakelijk om te 
kijken of TDM ook toegepast kan worden bij andere biologicals in de reumatologie 
(adalimumab, etanercept, tocilizumab, abatacept), biosimilars en bij andere aandoeningen 
(gastro-enterologie, dermatologie, oncologie).
categorieën een aparte aanpak vereist. Uiteraard blijft de behandeling van een patiënt 
met therapeutische normale spiegels ongewijzigd. Bij patiënten met te hoge (supra-
therapeutische) spiegels, kan de dosis infliximab worden verlaagd om zo de kans op dosis 
afhankelijke bijwerkingen te verkleinen en ook kosten te besparen. 
Een laatste groep vormen de patiënten met een lage ziekteactiviteit en non-
therapeutische spiegels. Bij deze groep patiënten is het nuttig om te weten hoe lang de 
patiënt non-therapeutische (therapeutisch te lage) spiegels in zijn bloed heeft. Immers, 
wanneer een patiënt gedurende lange tijd (bijvoorbeeld langer dan 6 maanden) van het 
infusie-interval non-therapeutische spiegels heeft, lijkt de lage ziekteactiviteit van de 
patiënt niet dankzij de infliximab te zijn ontstaan. 
Meer inzicht is dus nodig, op welk moment in het infusie-interval bij patiënten met 
een waarschijnlijk non-therapeutische dalspiegel deze dalspiegels ontstaan. Daarnaast is 
het belangrijk om te weten, hoe snel anti-infliximab antistoffen gevormd worden, om zo 
meer inzicht te krijgen in de farmacokinetiek van infliximab. Bovenstaande vragen zijn 
uitgezocht in een kinetische studie bij 27 patiënten en worden beschreven in hoofdstuk 
3.3. In deze studie bleek dat bij patiënten die anti-infliximab antistoffen vormen, deze 
antistoffen al halverwege het infuusinterval zichtbaar waren. Dat betekent dat  patiënten 
die antilichamen vormen al vanaf dat moment non-therapeutische spiegels in het bloed 
hebben. Dit in tegenstelling tot patiënten waarbij geen anti-infliximab antilichamen 
aangetoond konden worden: geen van deze patiënten had non-therapeutische spiegels 
halverwege het infusieinterval. Op basis hiervan kan geconcludeerd worden dat de 
aanwezigheid van anti-infliximab antistoffen vlak voor het infuus, een sensitieve en 
specifieke voorspeller zijn voor non-therapeutische infliximab spiegels halverwege het 
infuus. 
Hoofdstuk 3.4
Ondanks het feit dat verschillende wetenschappelijke onderzoeken suggereren dat de 
bepaling van (anti-)infliximab dalspiegels kan worden gebruikt om de behandeling van 
infliximab te optimaliseren, is er tot op heden nog geen prospectieve studie gedaan om 
de testkarakteristieken vast te stellen van (anti)infliximab bepalingen in vergelijking tot 
standaard ziekte-activiteit gestuurde zorg. Het onderzoek dat beschreven wordt in 
hoofdstuk 3.4. geeft duidelijke aanwijzingen dat TDM op twee verschillende momenten 
toegepast kan worden: enerzijds om reeds na 6 weken al het te verwachten effect na 6 
maanden te kunnen voorspellen. Anderzijds lijkt TDM zeker ook geschikt om patiënten op 
te sporen die ondanks lage/afwezige infliximabspiegels toch een lage ziekte-activteit 
hebben. TDM bleek overigens niet geschikt om te voorspellen welke patiënt in aanmerking 
zou kunnen komen voor een dosisverhoging.
Hoofdstuk 3.5
Anti-infliximab antistoffen komen bij 8-43% van de RA patiënten voor, en kunnen 
leiden tot sterk verminderde of zelfs afwezige infliximab-spiegels. Een behandeling die de 
vorming van anti-infliximab tegen gaat of vermindert zal derhalve de effectiviteit van 
infliximab kunnen verbeteren
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Verder onderzoek naar interventies afgestemd op de individuele eigenschappen van 
de patiënt lijken een belangrijke bijdrage te kunnen leveren aan de optimalisatie van het 
geneesmiddelgebruik van patiënten met reumatoïde artritis: zowel bij therapietrouw als 
bij TDM. Hierbij is een multidisciplinaire aanpak vereist, waarin onder andere 
reumatologen, apothekers, psychologen en/of laboranten hun kennis delen, om zo samen 
effectieve zorginterventies te ontwikkelen.
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